[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 175
1. Rao M, Sagar P, Duff S, Hulme-Moir M, Brayshaw I: Laparoscopic excision of a retrorectal schwannoma. Tech Coloproctol; 2010 Dec;14(4):353-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Retrorectal tumors are uncommon and are usually managed by open surgical excision.
  • Recent advances in laparoscopic techniques have led to the use of laparoscopy for a variety of problems in colorectal surgery, including the excision of retrorectal tumours.
  • This case report, which describes the laparoscopic excision of a benign schwannoma arising from the second sacral nerve root, highlights the benefits of accurate preoperative diagnosis with MR imaging and the advantages of a laparoscopic approach while pointing out principles that should be adhered to when using this approach.
  • The tumour was successfully resected without neural compromise and with a prompt and full postoperative recovery.
  • [MeSH-major] Laparoscopy. Neurilemmoma / surgery. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1663-5 [15937628.001]
  • [Cites] Br J Surg. 2008 Feb;95(2):214-21 [17933000.001]
  • [Cites] Dis Colon Rectum. 1985 Sep;28(9):644-52 [2996861.001]
  • (PMID = 20454822.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


2. Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S, Giannopoulos A, Mantzoros CS: Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev; 2007 Feb;16(2):308-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Adiponectin, an adipocyte-secreted hormone with insulin-sensitizing effects, has been inversely associated with several hormonally dependent malignancies, including breast, endometrial, and colorectal cancer.
  • Few studies have examined serum adiponectin in relation to prostate cancer, and expression of adiponectin receptors has previously not been assessed in prostate tumors.
  • EXPERIMENTAL DESIGN: We collected plasma samples and covariate data in the context of a case-control study of 300 Greek men, including 75 prostate cancer cases, 75 patients with benign prostatic hyperplasia (BPH), and 150 healthy controls.
  • Malignant prostate tissue samples have reduced expression of adiponectin receptors as compared with benign prostate tissue.
  • [MeSH-major] Adiponectin / blood. Biomarkers, Tumor / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / metabolism. Receptors, Cell Surface / metabolism


3. Hauenschild L, Bader FG, Laubert T, Czymek R, Hildebrand P, Roblick UJ, Bruch HP, Mirow L: Laparoscopic colorectal resection for benign polyps not suitable for endoscopic polypectomy. Int J Colorectal Dis; 2009 Jul;24(7):755-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colorectal resection for benign polyps not suitable for endoscopic polypectomy.
  • BACKGROUND AND AIMS: Endoscopic polypectomy still remains the cornerstone of therapy for colorectal polyps and adenomas.
  • However, if colorectal polyps are too large or not accessible for endoscopic ablation or cannot be removed without an increased risk for perforation, operative procedures are required.
  • In patients which could not be treated by endoscopic polypectomy due to size, location, and/or risk of complications, a laparoscopic colorectal resection was performed.
  • All data were prospectively assessed in our "colorectal resection" database.
  • RESULTS: The database analysis revealed 58 patients with endoscopically not resectable colorectal polyps who underwent a laparoscopic colorectal resection (intend to treat).
  • The histopathological work-up revealed benign disease in all cases.
  • CONCLUSION: Laparoscopic resection of colorectal polyps is a safe and minimally invasive technique for the management of benign colorectal tumors.
  • [MeSH-major] Colonic Polyps / pathology. Colonic Polyps / surgery. Colorectal Surgery. Endoscopy. Laparoscopy

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2007 Oct;246(4):655-62; discussion 662-4 [17893502.001]
  • [Cites] Arch Surg. 2004 Jan;139(1):39-42 [14718273.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Chirurg. 2003 Oct;74(10):966-80; quiz 981-2 [15017996.001]
  • [Cites] Rev Esp Enferm Dig. 2004 May;96(5):315-21 [15180443.001]
  • [Cites] J Gastrointest Surg. 2009 Feb;13(2):275-81 [18941844.001]
  • [Cites] World J Surg. 2002 Mar;26(3):377-83 [11865378.001]
  • [Cites] Surg Endosc. 1997 Jun;11(6):643-4 [9171124.001]
  • [Cites] Surg Endosc. 2003 Sep;17(9):1461-3 [12739115.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1380-3 [14530679.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1341-4 [9788858.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):34-41 [16012932.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3061-8 [17634484.001]
  • [Cites] Tech Coloproctol. 2004 Dec;8 Suppl 2:s243-7 [15666099.001]
  • [Cites] Cancer. 1989 Nov 1;64(9):1937-47 [2477139.001]
  • [Cites] Tech Coloproctol. 2004 Dec;8 Suppl 2:s283-90 [15666108.001]
  • [Cites] Br J Surg. 1993 Jun;80(6):788-93 [8330178.001]
  • [Cites] Surg Endosc. 1997 Feb;11(2):119-22 [9069140.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1246-9 [11005491.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Dis Colon Rectum. 2001 May;44(5):746-8 [11357040.001]
  • [Cites] Ann Surg. 2008 Jul;248(1):1-7 [18580199.001]
  • [Cites] Tech Coloproctol. 2004 Dec;8 Suppl 2:s291-4 [15666109.001]
  • [Cites] Onkologie. 2001 Feb;24(1):29-32 [11441277.001]
  • [Cites] Mayo Clin Proc. 2000 Apr;75(4):344-8 [10761487.001]
  • [Cites] Dig Dis. 2005;23(2):127-34 [16352892.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Surg Endosc. 2005 Sep;19(9):1252-5 [16132333.001]
  • [Cites] Gastrointest Endosc. 2004 Aug;60(2):234-41 [15278051.001]
  • [Cites] Surg Endosc. 2001 Feb;15(2):116-20 [11285950.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):400-3 [17180271.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):505-8 [10215825.001]
  • (PMID = 19283390.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


Advertisement
4. Gopalan A, Sharp DS, Fine SW, Tickoo SK, Herr HW, Reuter VE, Olgac S: Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol; 2009 May;33(5):659-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: We reviewed histologic material and clinical data from 24 cases selected from a database of 67 dome-based tumors diagnosed and treated at our institution from 1984 to 2005.
  • RESULT: The mean age at diagnosis was 52 years (range: 26 to 68 y).
  • In all instances but 1, cystitis cystica/glandularis was focal and predominantly in the bladder overlying the urachal neoplasm.
  • Urachal remnants were identified in 15 cases: the urachal epithelium was benign urothelial-type in 6 cases and showed adenomatous changes in 9.
  • In all 3, urachal remnants were identified and showed transition from benign to adenomatous epithelium.
  • On immunohistochemistry, these tumors were positive for CK20 and variably positive for CK7 and 34BE12.
  • Surface urothelial involvement by carcinoma and presence of cystitis cystica/glandularis do not necessarily exclude the diagnosis of urachal carcinoma.
  • Immunostains do not unequivocally discriminate a urachal from a colorectal carcinoma, but diffuse positivity for 34BE12 would support, and diffuse nuclear immunoreactivity for beta-catenin would militate against, a diagnosis of urachal carcinoma.
  • Local recurrence may be owing to seeding within the distal urothelial tract, particularly in tumors with a configuration that is polypoid and which open into the bladder cavity.
  • [MeSH-major] Carcinoma / pathology. Urachus / pathology. Urinary Bladder Neoplasms / pathology. Urothelium / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Signet Ring Cell / pathology. Chemotherapy, Adjuvant. Cystectomy. Cystitis / pathology. Databases as Topic. Female. Homeodomain Proteins / analysis. Humans. Immunohistochemistry. Keratin-20 / analysis. Keratin-7 / analysis. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy, Adjuvant. Treatment Outcome. Umbilicus / surgery. beta Catenin / analysis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1380-7 [11684954.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2434-40 [17932892.001]
  • [Cites] J Urol. 2003 Apr;169(4):1295-8 [12629346.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):456-9 [15043458.001]
  • [Cites] J Urol. 1982 Jan;127(1):40-2 [7057501.001]
  • [Cites] Urology. 1983 Apr;21(4):360-6 [6836822.001]
  • [Cites] J Urol. 1984 Jan;131(1):1-8 [6361280.001]
  • [Cites] Urol Res. 1983;11(5):235-8 [6659216.001]
  • [Cites] Urology. 1985 Sep;26(3):218-21 [4035835.001]
  • [Cites] J Urol. 1986 Jun;135(6):1240-4 [3712579.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2165-72 [1706216.001]
  • [Cites] J Urol. 1994 Feb;151(2):365-6 [8283526.001]
  • [Cites] Hum Pathol. 1996 Mar;27(3):240-7 [8600037.001]
  • [Cites] Cancer. 1955 Jul-Aug;8(4):741-58 [13240656.001]
  • [Cites] Mod Pathol. 2005 Sep;18(9):1217-22 [15803184.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):69-87 [16512600.001]
  • [Cites] J Urol. 2006 Jun;175(6):2042-7; discussion 2047 [16697798.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):712-20 [16826585.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):721-8 [16826584.001]
  • [Cites] J Urol. 2007 Jul;178(1):74-8; discussion 78 [17499279.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • (PMID = 19252435.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082088
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / CTNNB1 protein, human; 0 / Homeodomain Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / beta Catenin
  • [Other-IDs] NLM/ NIHMS627175; NLM/ PMC4225778
  •  go-up   go-down


5. Brankovic B, Radisavljevic M, Radojkovic M, Stanojevic G, Stojanovic M, Nagorni A, Radojkovic D, Jeremic L, Nestorovic M, Karamarkovic A: Nonfunctional retroperitoneal paraganglioma presenting as acute upper gastrointestinal hemorrhage. Hepatogastroenterology; 2010 Mar-Apr;57(98):288-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Paragangliomas are very rare tumors arising from extraadrenal chromaffin cells.
  • Clinical presentation of benign retroperitoneal nonfunctional paraganglioma is unspecific.
  • Symptoms may occur when tumor attains a remarkable size or when complications arise.
  • This article reports a case of nonfunctional retroperitoneal paraganglioma as a cause of acute upper gastrointestinal hemorrhage which represents the unusual urgent clinical manifestation of these tumors.
  • The presented case emphasizes the necessity to include extraadrenal paraganglioma in the differential diagnosis in all patients with retroperitoneal mass found even in the presence of at first appearance non-related emergency condition like acute upper gastrointestinal bleeding.
  • [MeSH-major] Gastrointestinal Hemorrhage / diagnosis. Paraganglioma / diagnosis. Retroperitoneal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583429.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


6. Campos FG, Valarini R: Evolution of laparoscopic colorectal surgery in Brazil: results of 4744 patients from the national registry. Surg Laparosc Endosc Percutan Tech; 2009 Jun;19(3):249-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolution of laparoscopic colorectal surgery in Brazil: results of 4744 patients from the national registry.
  • BACKGROUND: Since its introduction, laparoscopic colorectal surgery has raised intense debate and controversies regarding its safety and effectiveness.
  • METHODS: This multicentric registry reports the experience of 28 Brazilian surgical teams specializing in laparoscopic colorectal surgery.
  • Benign diseases were diagnosed in 2356 patients (49.6%).
  • Two thousand three hundred and eighty-nine (50.4%) malignant tumors were operated upon, and histologic classification showed 2347 (98%) adenocarcinomas, 30 (0.6%) spinocelular carcinomas, and 12 (0.2%) other histologic types.
  • Tumor recurrence rate was 16.3% among patients followed more than 1 year.
  • Compared with other registries, there was a 75% increase in the number of groups performing laparoscopic colorectal surgery and a decrease in conversions (from 10.5% to 5.5%) and mortality (from 1.5% to 0.9%) rates.
  • (2) operative indications for benign and malignant diseases were similar, and diverticular disease of the colon comprised 40% of the benign ones;.

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542856.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Castillo OA, Vitagliano G, Kerkebe M, Parma P, Pinto I, Diaz M: Laparoscopic adrenalectomy for suspected metastasis of adrenal glands: our experience. Urology; 2007 Apr;69(4):637-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 34 adrenalectomies were performed in 32 patients for incidental adrenal masses discovered at primary tumor diagnosis or during follow-up.
  • The primary tumors diagnosed were 13 cases of lung carcinoma, 9 of renal cell carcinoma, 2 of colorectal carcinoma, 2 of bladder carcinoma, and 1 each of ovarian carcinoma, breast cancer, gastric cancer, and melanoma.
  • Two patients had no history of a primary tumor.
  • The mean tumor size was 4.3 cm (range 1.5 to 9).
  • The microscopic analysis revealed 22 malign lesions (64.7%) and 12 cases of benign pathologic features (35.3%).
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Laparoscopy

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17445640.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Hewitt MJ, Wood N, Quinton ND, Charlton R, Taylor G, Sheridan E, Duffy SR: The detection of microsatellite instability in blind endometrial samples--a potential novel screening tool for endometrial cancer in women from hereditary nonpolyposis colorectal cancer families? Int J Gynecol Cancer; 2006 May-Jun;16(3):1393-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The detection of microsatellite instability in blind endometrial samples--a potential novel screening tool for endometrial cancer in women from hereditary nonpolyposis colorectal cancer families?
  • Microsatellite instability (MSI) is the phenotypic molecular characteristic of the majority of tumors associated with the hereditary nonpolyposis colorectal cancer syndrome (HNPCC).
  • Twenty-four women with EC, 20 women from HNPCC kindreds, and 20 women undergoing gynecological surgery for benign indications underwent blind sampling.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / genetics. Genomic Instability. Microsatellite Repeats
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / pathology. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / pathology. Family Health. Female. Humans. Middle Aged. Molecular Diagnostic Techniques / methods. Single-Blind Method

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803536.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Zitt M, Zitt M, Müller HM: DNA methylation in colorectal cancer--impact on screening and therapy monitoring modalities? Dis Markers; 2007;23(1-2):51-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA methylation in colorectal cancer--impact on screening and therapy monitoring modalities?
  • Colorectal cancer (CRC) is a common malignancy.
  • It arises from benign neoplasms and evolves into adenocarcinomas through a stepwise histological progression sequence, proceeding from either adenomas or hyperplastic polyps/serrated adenomas.
  • DNA methylation changes have been recognized as one of the most common molecular alterations in human tumors, including CRC.
  • [MeSH-major] Colorectal Neoplasms / metabolism. DNA Methylation. Mass Screening

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325426.001).
  • [ISSN] 0278-0240
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 160
  • [Other-IDs] NLM/ PMC3851076
  •  go-up   go-down


10. DeFeo EM, Cheng LL: Characterizing human cancer metabolomics with ex vivo 1H HRMAS MRS. Technol Cancer Res Treat; 2010 Aug;9(4):381-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Publications of proton high resolution magic angle spinning (1H HRMAS) magnetic resonance spectroscopy (MRS) and its role in identification of metabolic markers for human cancer reported between 2005 and 2009 are reviewed according the anatomic sites of cancer: lung, breast, prostate, brain, colorectal, and cervical.
  • 1H HRMAS MRS is a valuable tool that can elucidate relevant biological metabolite information that is being used to distinguish cancer from benign tissue, and even classify types of tumors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Magnetic Resonance Spectroscopy. Metabolomics. Neoplasms / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20626203.001).
  • [ISSN] 1533-0338
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA115746; United States / NCI NIH HHS / CA / CA115746-04S2; United States / NCI NIH HHS / CA / CA141139
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


11. Yoon HE, Fukuhara K, Michiura T, Takada M, Imakita M, Nonaka K, Iwase K: Pulmonary nodules 10 mm or less in diameter with ground-glass opacity component detected by high-resolution computed tomography have a high possibility of malignancy. Jpn J Thorac Cardiovasc Surg; 2005 Jan;53(1):22-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: For the histological diagnosis of small lung cancers of 10 mm or less in diameter (< or =10), resection by video-assisted thoracic surgery (VATS) with computed tomography (CT)-guided marking is feasible.
  • RESULTS: The histology of all 94 nodules showed 52 primary lung cancers, 6 metastatic tumors, 5 benign tumors, 8 intrapulmonary lymph nodes, and 23 inflammatory nodules.
  • [MeSH-major] Carcinoma, Small Cell / diagnostic imaging. Carcinoma, Small Cell / pathology. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / pathology. Solitary Pulmonary Nodule / diagnostic imaging. Solitary Pulmonary Nodule / pathology. Tomography, X-Ray Computed
  • [MeSH-minor] Colorectal Neoplasms / diagnostic imaging. Colorectal Neoplasms / pathology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Patient Selection. Predictive Value of Tests. Retrospective Studies. Thoracic Surgery, Video-Assisted

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1996 Dec;201(3):798-802 [8939234.001]
  • [Cites] Chest. 1977 Oct;72(4):474-6 [908215.001]
  • [Cites] Arch Intern Med. 1997 Apr 28;157(8):849-55 [9129544.001]
  • [Cites] Br J Radiol. 2000 Dec;73(876):1252-9 [11205667.001]
  • [Cites] Lancet. 1999 Jul 10;354(9173):99-105 [10408484.001]
  • [Cites] Ann Thorac Surg. 2003 May;75(5):1601-5; discussion 1605-6 [12735586.001]
  • [Cites] Chest. 1996 Apr;109 (4):982-8 [8635381.001]
  • [Cites] Lung Cancer. 2001 Dec;34(3):325-32 [11714529.001]
  • [Cites] Br J Cancer. 2001 Nov 2;85(9):1326-31 [11720469.001]
  • [Cites] J Thorac Cardiovasc Surg. 1995 Jan;109(1):120-9 [7815787.001]
  • [Cites] Am Rev Respir Dis. 1984 Oct;130(4):561-5 [6091507.001]
  • [Cites] AJR Am J Roentgenol. 1996 Jul;167(1):105-9 [8659351.001]
  • [Cites] Cancer. 1996 May 1;77(9):1947-55 [8646697.001]
  • [Cites] Clin Imaging. 1997 Nov-Dec;21(6):390-9 [9391729.001]
  • [Cites] Am Rev Respir Dis. 1984 Oct;130(4):549-54 [6091505.001]
  • [Cites] Am Rev Respir Dis. 1983 Dec;128(6):1090-2 [6650983.001]
  • [Cites] Kyobu Geka. 1994 Jan;47(1):4-9 [8277631.001]
  • [Cites] Kyobu Geka. 1994 Jan;47(1):28-32 [8277628.001]
  • (PMID = 15724498.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Braendle W, Kuhl H, Mueck A, Birkhäuser M, Thaler C, Kiesel L, Neulen J: [Does hormonal contraception increase the risk for tumors?]. Ther Umsch; 2009 Feb;66(2):129-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Does hormonal contraception increase the risk for tumors?].
  • A non-contraceptive benefit of oral hormonal contraceptives (OC) is a diminished risk for certain benign as well as malignant tumours, such as benign breast tumours, uterine fibroids and ovarian cysts.
  • Long-term use of OC leads to a decreased risk of endometrial and colorectal carcinomata.
  • [MeSH-major] Contraceptives, Oral, Hormonal / adverse effects. Neoplasms / chemically induced
  • [MeSH-minor] Adult. Age Factors. Case-Control Studies. Female. Genital Neoplasms, Female / chemically induced. Genital Neoplasms, Female / genetics. Humans. Long-Term Care. Middle Aged. Risk Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19180433.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Contraceptives, Oral, Hormonal
  • [Number-of-references] 47
  •  go-up   go-down


13. Cherqui D, Laurent A, Tayar C, Karoui M: [Laparoscopic hepatectomy]. Bull Acad Natl Med; 2007 Nov;191(8):1661-81; discussion 1681-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The indications were benign in 65 cases (40%) and malignant in 94 cases (60%).
  • The most frequent benign disorders were symptomatic hepatocyte tumors and tumors of uncertain nature (adenomas and focal nodular hyperplasia in 40 cases).
  • The malignant lesions comprised 60 cases of hepatocellular carcinoma on a cirrhotic liver and 20 metastases of colorectal cancer.
  • The tumors had a diameter of 44 mm (range 4-170 mm).
  • The mean resection margin for malignant tumors was 14 mm and there were no relapses on the trocar ports.
  • [MeSH-minor] Female. Humans. Liver Neoplasms / surgery. Male. Surgical Instruments

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18666465.001).
  • [ISSN] 0001-4079
  • [Journal-full-title] Bulletin de l'Académie nationale de médecine
  • [ISO-abbreviation] Bull. Acad. Natl. Med.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


14. Olesen SH, Christensen LL, Sørensen FB, Cabezón T, Laurberg S, Orntoft TF, Birkenkamp-Demtröder K: Human FK506 binding protein 65 is associated with colorectal cancer. Mol Cell Proteomics; 2005 Apr;4(4):534-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human FK506 binding protein 65 is associated with colorectal cancer.
  • We initiated the present study to identify new genes associated with colorectal cancer.
  • In a previously published microarray study an EST (W80763), later identified as the gene hFKBP10 (NM_021939), was found to be strongly expressed in tumors while absent in the normal mucosa.
  • Here we describe this gene hFKBP10 together with its encoded protein hFKBP65 as a novel marker associated with colorectal cancer.
  • Analysis of 31 colorectal adenocarcinomas and 14 normal colorectal mucosa by RealTime PCR for hFKBP10 showed a significant up-regulation in tumors, when compared with normal mucosa.
  • Immunohistochemical analysis of 26 adenocarcinomas and matching normal mucosa, as well as benign hyperplastic polyps and adenomas, using a monoclonal anti-hFKBP65 antibody, showed that the protein was not present in normal colorectal epithelial cells, but strongly expressed in the tumor cells of colorectal cancer.
  • The protein was also expressed in fibroblasts of both normal mucosa and tumor tissue.
  • Western blot analysis of matched tumors and normal mucosa supported the finding of increased hFKBP65 expression in tumors compared with normal mucosa, in addition to identifying the molecular mass of hFKBP65 to approximately 72 kDa.
  • In conclusion, the protein hFKBP65 is associated with colorectal cancer, and we hypothesize the protein to be involved in fibroblast and transformed epithelial cell-specific protein synthesis in the endoplasmic reticulum.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Tacrolimus Binding Proteins / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671042.001).
  • [ISSN] 1535-9476
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; EC 5.2.1.- / Tacrolimus Binding Proteins
  •  go-up   go-down


15. Nieuwenhuis DH, Draaisma WA, Verberne GH, van Overbeeke AJ, Consten EC: Transanal endoscopic operation for rectal lesions using two-dimensional visualization and standard endoscopic instruments: a prospective cohort study and comparison with the literature. Surg Endosc; 2009 Jan;23(1):80-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: All consecutive patients with benign or malignant pT1 or pT2 rectal lesions undergoing TEO were prospectively followed.
  • CONCLUSION: The study findings showed that for rectal tumors located up to 15 cm from the anal verge with a maximal diameter of 5 cm, TEO using standard laparoscopic instruments with a 2D view is feasible and provides results comparable with those associated with a 3D view and dedicated instruments.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma, Villous / surgery. Endoscopes. Endoscopy. Rectal Neoplasms / surgery. Surgery, Computer-Assisted / instrumentation

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1997 May;84(5):652-6 [9171754.001]
  • [Cites] Lancet. 1993 Feb 20;341(8843):457-60 [8094488.001]
  • [Cites] Surg Endosc. 2000 Jan;14(1):71-4 [10653241.001]
  • [Cites] Dis Colon Rectum. 1992 Dec;35(12):1183-91 [1473424.001]
  • [Cites] Br J Surg. 1997 Mar;84(3):348-51 [9117305.001]
  • [Cites] Surg Endosc. 1988;2(2):71-5 [3413659.001]
  • [Cites] Endoscopy. 1985 Jan;17(1):31-5 [3971938.001]
  • [Cites] Surg Clin North Am. 2006 Aug;86(4):915-25 [16905416.001]
  • [Cites] Dig Surg. 2006;23(1-2):12-22 [16675907.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1292-7 [12739122.001]
  • [Cites] J Am Coll Surg. 1996 Jun;182(6):495-502 [8646349.001]
  • [Cites] Br J Surg. 2005 Dec;92(12):1546-52 [16252312.001]
  • [Cites] Surg Oncol Clin N Am. 2001 Jul;10(3):709-31, xi [11685937.001]
  • [Cites] Dig Dis. 2007;25(1):76-9 [17384511.001]
  • [Cites] Colorectal Dis. 2006 Nov;8(9):795-9 [17032328.001]
  • [Cites] Eur J Surg Oncol. 1994 Dec;20(6):658-66 [7995418.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):904-10 [11978515.001]
  • [Cites] J Gastrointest Surg. 2007 Feb;11(2):155-7 [17390166.001]
  • [Cites] Surg Technol Int. 2005;14:131-7 [16525965.001]
  • [Cites] J Nippon Med Sch. 2005 Oct;72(5):278-84 [16247227.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1106-11 [14597451.001]
  • [Cites] Dis Colon Rectum. 1996 Sep;39(9):969-76 [8797643.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1224-6 [7953369.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]
  • [Cites] Colorectal Dis. 2007 Mar;9(3):229-34 [17298620.001]
  • [Cites] Dig Surg. 2005;22(1-2):6-15 [15761225.001]
  • (PMID = 18443874.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Schmidt WM, Sedivy R, Forstner B, Steger GG, Zöchbauer-Müller S, Mader RM: Progressive up-regulation of genes encoding DNA methyltransferases in the colorectal adenoma-carcinoma sequence. Mol Carcinog; 2007 Sep;46(9):766-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive up-regulation of genes encoding DNA methyltransferases in the colorectal adenoma-carcinoma sequence.
  • Here, we investigated the expression of DNA demethylase and three DNA methyltransferases during colorectal tumorigenesis comparing the genes encoding DNA methyltransferases 1 (DNMT1), 3A, and 3B (DNMT3A and DNMT3B) with methyl-CpG binding domain protein 2 (MBD2), recently described as the only active DNA demethylase.
  • Total RNA isolated from normal colonic mucosa (n = 24), benign adenomas (n = 18), and malignant colorectal carcinomas (n = 32) was analyzed by reverse transcriptase-PCR with subsequent quantification by capillary gel electrophoresis.
  • In contrast to MBD2, expression of DNMT1 and DNMT3A increased in parallel to the degree of dysplasia, with significant overexpression in the malignant lesion when compared with mucosa or with benign lesions (DNMT1).
  • Pairwise comparisons between tumors and matched, adjacent healthy mucosa tissue (n = 13) revealed that expression of all three genes encoding DNA methyltransferases increased by two- to three-fold.
  • Our data suggest a relevant role of the DNA methyltransferases during colorectal tumorigenesis.
  • [MeSH-major] Adenoma / enzymology. Colorectal Neoplasms / enzymology. DNA Modification Methylases / metabolism. Gene Expression Regulation, Neoplastic. Up-Regulation

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17538945.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DMAP1 protein, human; 0 / DNA-Binding Proteins; 0 / MBD2 protein, human; 0 / Repressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA methyltransferase 3A; EC 2.1.1.37 / DNA methyltransferase 3B
  •  go-up   go-down


17. Satgé D, Sasco AJ, Vekemans MJ, Portal ML, Fléjou JF: Aspects of digestive tract tumors in Down syndrome: a literature review. Dig Dis Sci; 2006 Nov;51(11):2053-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aspects of digestive tract tumors in Down syndrome: a literature review.
  • The purpose of this study was to describe the digestive neoplasms found in persons with Down syndrome.
  • Due to intellectual disability, persons with Down syndrome do not convey their symptoms and pain, leading to delayed diagnosis and potentially worse outcome.
  • It is thus important to know which organs are at risk for tumors and possible tumor risk factors.
  • In a review of the literature, we found 13 benign tumors and 127 cancers in 1 fetus, 8 children, and 131 adults with Down syndrome.
  • The review suggests a decreased incidence of digestive cancer, however, with a possible increased incidence of neoplasms of the pancreas and gallbladder.
  • This review may allow a more specific, adapted medical follow-up for persons with Down syndrome and could help to elucidate the oncogenesis of digestive neoplasms.
  • [MeSH-major] Digestive System Neoplasms / epidemiology. Down Syndrome / epidemiology
  • [MeSH-minor] Colorectal Neoplasms / epidemiology. Comorbidity. Esophageal Neoplasms / epidemiology. Incidence. Liver Neoplasms / epidemiology. Oropharyngeal Neoplasms / epidemiology. Pancreatic Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Jan 15;355(9199):165-9 [10675114.001]
  • [Cites] Lancet. 1997 Feb 15;349(9050):485-9 [9040589.001]
  • [Cites] Acta Paediatr. 1998 Dec;87(12):1307-9 [9894836.001]
  • [Cites] J Nutr. 2000 Feb;130(2):129-32 [10720158.001]
  • [Cites] Oncogene. 1998 May;16(20):2687-93 [9632145.001]
  • [Cites] J Intellect Disabil Res. 1993 Dec;37 ( Pt 6):543-51 [8124000.001]
  • [Cites] Science. 1997 Nov 21;278(5342):1464-6 [9367959.001]
  • [Cites] Int J Oncol. 2000 Aug;17(2):245-52 [10891531.001]
  • [Cites] Cancer Causes Control. 2004 Dec;15(10):1021-5 [15801486.001]
  • [Cites] Arch Dis Child. 2004 Nov;89(11):1014-7 [15499053.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):599-612 [6295193.001]
  • [Cites] J Am Diet Assoc. 1996 Dec;96(12):1262-7 [8948387.001]
  • [Cites] Dev Med Child Neurol. 1982 Dec;24(6):817-29 [6218002.001]
  • [Cites] Prog Pediatr Surg. 1977;10:33-4 [141055.001]
  • [Cites] J Intellect Disabil Res. 1997 Aug;41 ( Pt 4):312-6 [9297608.001]
  • [Cites] Am J Med Genet. 1993 Jun 15;46(5):612 [8322833.001]
  • [Cites] J Ment Defic Res. 1989 Apr;33 ( Pt 2):185-7 [2542562.001]
  • [Cites] J Am Acad Dermatol. 1991 Nov;25(5 Pt 2):909-11 [1837034.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Oct-Nov;20(7):517-29 [12959856.001]
  • [Cites] J Oral Maxillofac Surg. 1992 Oct;50(10):1087-90 [1388203.001]
  • [Cites] Ned Tijdschr Geneeskd. 1996 Oct 19;140(42):2083-7 [8965950.001]
  • [Cites] J Biol Chem. 1998 Jul 24;273(30):18871-80 [9668063.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Apr;18(4):318-21 [9087574.001]
  • [Cites] Hum Genet. 1989 Jun;82(3):291-2 [2525108.001]
  • [Cites] Langenbecks Arch Surg. 2001 Apr;386(3):224-9 [11382326.001]
  • [Cites] Cancer. 2002 Nov 1;95(9):1946-53 [12404289.001]
  • [Cites] J Intellect Disabil Res. 2001 Jun;45(Pt 3):219-25 [11422646.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Dec;26(4):312-21 [10534766.001]
  • [Cites] J Postgrad Med. 1998 Jan-Mar;44(1):16-8 [10703561.001]
  • [Cites] Downs Syndr Res Pract. 2002 Mar;8(1):31-6 [11915436.001]
  • [Cites] Tumori. 2003 Mar-Apr;89(2):193-5 [12841670.001]
  • [Cites] Int J Cancer. 2001 Sep 1;93(5):741-4 [11477589.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1997 Jun;9(6):589-92 [9222731.001]
  • [Cites] Cancer Genet Cytogenet. 2005 May;159(1):37-43 [15860355.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Jan;21(1):1 [9443035.001]
  • [Cites] Int J Cancer. 2001 Feb 1;91(3):350-8 [11169959.001]
  • [Cites] Arch Intern Med. 2003 Mar 24;163(6):705-11 [12639204.001]
  • [Cites] Mil Med. 1995 Sep;160(9):477-9 [7478037.001]
  • [Cites] Lancet. 2000 Dec 2;356(9245):1882-7 [11130384.001]
  • [Cites] Science. 1996 Oct 11;274(5285):259-62 [8824193.001]
  • [Cites] J Natl Cancer Inst. 1968 May;40(5):1087-99 [5648134.001]
  • [Cites] Lancet. 2001 Aug 4;358(9279):356-61 [11502314.001]
  • [Cites] Lancet. 2003 Apr 12;361(9365):1281-9 [12699967.001]
  • [Cites] Ann Hum Genet. 2001 Mar;65(Pt 2):167-76 [11427176.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1907-17 [14667750.001]
  • [Cites] J Pediatr Surg. 1998 Sep;33(9):1380-2 [9766358.001]
  • [Cites] Arch Dis Child. 2001 Sep;85(3):242-3 [11517110.001]
  • [Cites] J Intellect Disabil Res. 2001 Aug;45(Pt 4):300-7 [11489051.001]
  • [Cites] Cancer Lett. 2003 Oct 8;200(1):25-31 [14550949.001]
  • [Cites] Dev Med Child Neurol. 2000 Oct;42(10):691-8 [11085298.001]
  • [Cites] World J Gastroenterol. 2003 Feb;9(2):205-8 [12532432.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Jan;18(1):59-65 [8993981.001]
  • [Cites] Eur J Pediatr. 1997 May;156(5):420-1 [9177993.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1198-205 [8108387.001]
  • [Cites] Br J Radiol. 1995 Jan;68(805):85-8 [7881890.001]
  • [Cites] Bristol Med Chir J. 1977 Jan-Apr;92(341-342):3-7 [612362.001]
  • [Cites] Acta Paediatr Scand. 1975 Mar;64(2):322-6 [124122.001]
  • [Cites] J Intellect Disabil Res. 1994 Feb;38 ( Pt 1):9-26 [8173229.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7375-8 [11606364.001]
  • [Cites] Acta Paediatr. 1999 Sep;88(9):953-6 [10519335.001]
  • [Cites] Am J Gastroenterol. 1997 Jun;92(6):1000-4 [9177519.001]
  • [Cites] Science. 2004 Oct 22;306(5696):687-90 [15499018.001]
  • [Cites] Am J Med Genet. 1998 Jul 7;78(3):207-16 [9677053.001]
  • [Cites] Br J Cancer. 1962 Jun;16:177-86 [13908377.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Jul;10(3):177-82 [7522040.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):88-95 [11391481.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1974 Feb;37(2):202-7 [4272495.001]
  • [Cites] Acta Paediatr. 1995 Jun;84(6):711-2 [7670266.001]
  • [Cites] Int J Cancer. 2005 Jan 1;113(1):168-70 [15386432.001]
  • [Cites] Cesk Gastroenterol Vyz. 1975 Jun;29(4):275-7 [124229.001]
  • [Cites] Br J Psychiatry. 1990 Apr;156:531-3 [2143684.001]
  • [Cites] Br J Radiol. 1975 Jan;48(565):16-8 [1109621.001]
  • [Cites] J Clin Gastroenterol. 1986 Apr;8(2):111-4 [2943789.001]
  • [Cites] J Thorac Cardiovasc Surg. 1976 Aug;72(2):315-8 [134182.001]
  • [Cites] Oncol Rep. 1999 Nov-Dec;6(6):1223-7 [10523685.001]
  • [Cites] Am J Ment Retard. 1991 Jan;95(4):397-403 [2003909.001]
  • [Cites] Am J Gastroenterol. 2001 Jun;96(6):1718-24 [11419820.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2004 Aug;39(2):187-91 [15269626.001]
  • [Cites] Cancer Lett. 2000 Oct 16;159(1):15-21 [10974401.001]
  • [Cites] Am J Med Genet. 1998 Jun 5;77(5):431-8 [9632176.001]
  • [Cites] Paediatr Perinat Epidemiol. 2000 Oct;14(4):372 [11101025.001]
  • [Cites] J Interferon Res. 1990 Oct;10(5):515-7 [2148760.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1019-25 [11937181.001]
  • [Cites] Am Fam Physician. 1997 Aug;56(2):485-94 [9262529.001]
  • [Cites] Surg Today. 1998;28(5):567-9 [9607913.001]
  • [Cites] Eur J Hum Genet. 2001 Nov;9(11):811-4 [11781696.001]
  • (PMID = 17009117.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 103
  •  go-up   go-down


18. Ma TL, Ni PH, Zhong J, Tan JH, Qiao MM, Jiang SH: Low expression of XIAP-associated factor 1 in human colorectal cancers. Chin J Dig Dis; 2005;6(1):10-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low expression of XIAP-associated factor 1 in human colorectal cancers.
  • The aims of the present study were: (i) to investigate the expression of XAF1 in human colorectal cancers (CRC) both in vitro and in vivo, and (ii) to evaluate the possibility of XAF1 as a new tumor marker.
  • The expression of XAF1 in tissue was relatively lower in primary CRC compared with a relatively higher level in benign colorectal tumors (P < 0.01).
  • Although the XAF1 expression in circulation of those with CRC was also lower than in those with benign tumors, there was no statistical significance (P > 0.05).
  • CONCLUSIONS: The present results suggest that the low expression of XAF1 in tumor tissue coincides with a similar level in the peripheral circulation, which contributes at least part to the malignant behavior of CRC.
  • Integrating the XAF1 relative expression value with the other three traditional tumor biomarkers created a four-parameter assay that significantly improved the rate of diagnosis of CRC.
  • [MeSH-major] Biomarkers, Tumor / blood. Colonic Neoplasms / genetics. Colonic Neoplasms / physiopathology. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Aged. Apoptosis. Case-Control Studies. Female. Gene Expression Profiling. Humans. Intracellular Signaling Peptides and Proteins. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Zinc Fingers

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667552.001).
  • [ISSN] 1443-9611
  • [Journal-full-title] Chinese journal of digestive diseases
  • [ISO-abbreviation] Chin J Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / XAF1 protein, human
  •  go-up   go-down


19. Uchiyama K, Ueno M, Ozawa S, Kiriyama S, Shigekawa Y, Yamaue H: Combined use of contrast-enhanced intraoperative ultrasonography and a fluorescence navigation system for identifying hepatic metastases. World J Surg; 2010 Dec;34(12):2953-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The purpose of this study was to assess the concomitant use of contrast-enhanced intraoperative ultrasound (CE-IOUS) using the new microbubble agent Sonazoid, and to assess the fluorescence navigation system (Photo Dynamic Eye, or PDE) using indocyanine green (ICG) as a novel tool for identifying colorectal metastatic lesions compared with preoperative contrast-enhanced multiple row-detected computed tomography (MDCT) and gadoxetic acid-enhanced MRI.
  • METHODS: Thirty-two patients who underwent a liver resection for colorectal metastatic carcinoma from 2008 to 2009 were included in the present study.
  • RESULTS: A total of 56 lesions were identified based on the histopathological findings of the biopsies and resected tissues; of these, 52 were confirmed to be metastases, whereas 4 were benign tumors.
  • [MeSH-major] Colorectal Neoplasms / pathology. Contrast Media. Fluorescent Dyes. Liver Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. INDOCYANINE GREEN .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Surg. 2009 Oct;35(10 ):1495-8 [19674039.001]
  • [Cites] AJR Am J Roentgenol. 2009 Jun;192(6):1675-81 [19457834.001]
  • [Cites] AJR Am J Roentgenol. 2009 Jan;192(1):180-7 [19098199.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):236-40 [16432357.001]
  • [Cites] World J Gastroenterol. 2007 Feb 28;13(8):1252-6 [17451209.001]
  • [Cites] J Ultrasound Med. 2009 Sep;28(9):1133-42 [19710210.001]
  • [Cites] J Surg Oncol. 2009 Jul 1;100(1):75-9 [19301311.001]
  • [Cites] Ann Surg Oncol. 2010 Jan;17(1):144-51 [19774415.001]
  • [Cites] J Ultrasound Med. 2009 Apr;28(4):439-48 [19321671.001]
  • [Cites] Jpn J Radiol. 2009 May;27(4):185-93 [19499310.001]
  • [Cites] Dig Surg. 2009;26(5):392-9 [19923827.001]
  • [Cites] Cancer. 2009 Jun 1;115(11):2491-504 [19326450.001]
  • [Cites] World J Surg. 2008 Aug;32(8):1763-7 [18543027.001]
  • [Cites] World J Gastroenterol. 2008 May 28;14 (20):3207-11 [18506927.001]
  • [Cites] Br J Surg. 2009 Nov;96(11):1289-94 [19847873.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14 (4):1347-55 [17253105.001]
  • [Cites] Dig Dis. 2009;27(2):114-24 [19546549.001]
  • (PMID = 20734045.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Ferric Compounds; 0 / Fluorescent Dyes; 0 / Oxides; 0 / Sonazoid; 0 / gadolinium ethoxybenzyl DTPA; E1UOL152H7 / Iron; IX6J1063HV / Indocyanine Green; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


20. Singhi AD, Montgomery EA: Colorectal granular cell tumor: a clinicopathologic study of 26 cases. Am J Surg Pathol; 2010 Aug;34(8):1186-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal granular cell tumor: a clinicopathologic study of 26 cases.
  • Granular cell tumor (GCT) is commonly located in the subcutaneous tissue and oral cavity, and uncommon in the gastrointestinal tract, in which the majority arises in the esophagus with over-representation in African Americans (AA).
  • We report the clinicopathologic features of 1 of the largest series to date of colorectal GCTs.
  • We reviewed the clinical features of 26 colorectal GCTs seen at our institution between the years 1995 to 2009, which included 24 biopsies, 1 low anterior resection, and 1 colectomy.
  • The majority of colorectal GCT involved the right colon (19/26, 73%) ranging in size from 0.2 to 1.8 cm (mean 0.6 cm).
  • Most neoplasms were encountered on routine colonoscopy (14/24, 64%), however 3 patients presented with hematochezia, 3 with changing bowel habits, 2 with Crohn disease, 1 with diverticular disease, and 1 with appendicitis.
  • Of the 20 cases available for histologic review, the tumors were noted to either be infiltrative (12/20, 60%) or marginated (8/20, 40%) involving either the mucosa (7/20, 35%), submucosa (10/20, 50%), or both (3/20, 15%).
  • The microscopic features were similar to those of GCTs found elsewhere, but many of the neoplasms differed by displaying nuclear pleomorphism (8/20, 40%), lymphoid cuffs (9/20, 45%), and focal calcification (7/20, 35%).
  • On immunochemistry, 18 of the neoplasms were stained for S-100 and all cases showed positive staining.
  • Although infrequently found in the colorectum, colorectal GCT typically presents incidentally on routine colonoscopy and involves the right colon; it is not over-represented in AA patients.
  • GCTs can have both an infiltrative or marginated growth pattern with a subset displaying nuclear pleomorphism, a lymphoid cuff, focal calcification, and reactive mucosal surface changes, which in our experience, may lead to misdiagnosis on colorectal mucosal biopsies.
  • Although GCTs were benign tumors in this series, if incompletely excised regrowth of the lesion may occur and therefore, follow-up may be warranted.
  • [MeSH-major] Adenocarcinoma / pathology. Colon / pathology. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biopsy. Colectomy. Colonoscopy. Female. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. S100 Proteins / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20661017.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


21. Galitskiĭ MV, Khomeriki SG, Nikiforov PA: [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy]. Eksp Klin Gastroenterol; 2009;(5):28-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy].
  • The cholecystectomy results in change of cholic acids flow into intestine.
  • Permanent type of the bile flow provokes the increase of proliferation of colic epithelial cells and increases the risk for development of right-sided colorectal tumors.
  • Meanwhile morphological features of colorectal tumors at the patients with cholecystectomy are still remaining to be clarified.
  • The goal of the study was to investigate immunohistochemical markers of proliferation and apoptosis in colorectal adenomas and adenocarcinomas at the patients with cholecystectomy.
  • 83 tumors and 49 samples of mucosa were immunostained with monoclonal mouse anti-human p53 protein (Dako) and monoclonal mouse anti-human Ki-67 antigen (Novocastra).
  • Thus, in benign colorectal tumors at the patients with retained function of gallbladder intensifying of epithelial cells proliferation is not accompanied with intensifying of apoptosis, and in malignant tumors a complete supression of apoptosis is observed.
  • The retaining of apoptosis in colorectal tumors compensates intensive proliferative activity with expectation of better prognosis.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / biosynthesis. Cell Proliferation. Cholecystectomy. Colon / metabolism. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Intestinal Mucosa / metabolism. Ki-67 Antigen / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205327.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


22. Baglioni S, Melean G, Gensini F, Santucci M, Scatizzi M, Papi L, Genuardi M: A kindred with MYH-associated polyposis and pilomatricomas. Am J Med Genet A; 2005 Apr 15;134A(2):212-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MYH-associated polyposis (MAP) is a recently described autosomal recessive form of familial adenomatous polyposis (FAP) associated with susceptibility to colorectal carcinoma (CRC).
  • Both siblings had a history of pilomatricomas, benign tumors derived from hair follicles, in childhood.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. DNA Glycosylases / genetics. Hair Diseases / pathology. Pilomatrixoma / pathology. Skin Neoplasms / pathology


23. Guillem JG, Chessin DB, Jeong SY, Kim W, Fogarty JM: Contemporary applications of transanal endoscopic microsurgery: technical innovations and limitations. Clin Colorectal Cancer; 2005 Nov;5(4):268-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Transanal endoscopic microsurgery (TEM) is a minimally invasive procedure used to transanally excise select benign and malignant tumors of the rectum.
  • PATIENTS AND METHODS: Thirty-two consecutive patients scheduled for TEM were identified from our prospectively maintained colorectal service database.
  • In addition, a PubMed literature search was performed with use of the key words "transanal endoscopic microsurgery," "TEM," "rectal tumor," and "rectal cancer."
  • RESULTS: Transanal endoscopic microsurgery was performed for rectal adenocarcinoma (n = 17; 53%), adenoma (n = 12; 38%), and carcinoid tumors (n = 3; 9%).
  • Median tumor location was 9 cm from the anal verge (range, 3-15 cm).
  • Reasons for inability to complete TEM included narrow rectal lumen or contour of bony pelvis prohibiting passage of the operating proctoscope into the upper rectum and inability to maintain the proctoscope in the rectal lumen with carbon dioxide insufflation because of the distal location of the tumor.
  • Innovations used in the excision of rectal tumors via TEM included the use of the harmonic scalpel, closure of the rectal defect with an extracorporeal slip knot, and a hybrid approach incorporating TEM and traditional transanal techniques.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Carcinoid Tumor / surgery. Colonoscopy / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Female. Humans. Male. Microsurgery. Middle Aged. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16356304.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Amato A: Colorectal gastrointestinal stromal tumor. Tech Coloproctol; 2010 Nov;14 Suppl 1:S91-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal gastrointestinal stromal tumor.
  • Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm arising in the digestive tract, with an estimated prevalence of 15-20 per 1,000,000.
  • Colorectal GISTs represent about 5-10% of the cases, mainly located in the rectum that is the third common site.
  • Benign GISTs are more common, but many tumors are of uncertain malignant potential; tumor size and rate of mitosis are still the most reliable criteria for assessing the risk of an aggressive behavior.
  • Surgery is the first-line treatment for resectable non-metastatic colorectal GIST.
  • Segmental colectomy with negative margins is recommended, and local excision is oncologically adequate in highly selected rectal tumors.
  • [MeSH-major] Colorectal Neoplasms. Gastrointestinal Stromal Tumors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1178-86 [14515284.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):705-12 [11034250.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S37-8 [12528771.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):383-9 [11296107.001]
  • [Cites] Am J Surg Pathol. 1983 Sep;7(6):507-19 [6625048.001]
  • [Cites] Am J Clin Pathol. 2007 Jan;127(1):89-96 [17145623.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):2006-11 [12957454.001]
  • [Cites] Int J Colorectal Dis. 2007 Aug;22(8):981-2 [16583196.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Eur J Surg Oncol. 2004 Dec;30(10):1098-103 [15522557.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Dis Colon Rectum. 2006 May;49(5):609-15 [16552495.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):14-24 [17072676.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S60-5 [12528774.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):526-32 [17139461.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1316-9 [15793646.001]
  • [Cites] J Surg Oncol. 2009 Jan 1;99(1):42-7 [18942073.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):109-14 [16639561.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1121-33 [11688571.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1091-5 [11021812.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):625-41 [12717247.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Feb;18(2):147-51 [12542597.001]
  • [Cites] Am J Surg. 2006 Jan;191(1):121-3 [16399120.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2325-31 [16710031.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):937-45 [10435564.001]
  • [Cites] Gastroenterol Clin Biol. 2007 Jun-Jul;31(6-7):585-93 [17646785.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):162-8 [15654796.001]
  • [Cites] Mod Pathol. 1998 Aug;11(8):728-34 [9720500.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1922-9 [15622586.001]
  • [Cites] Pol J Pathol. 2003;54(1):3-24 [12817876.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3282-90 [15161681.001]
  • [Cites] Surg Today. 2007;37(6):455-9 [17522761.001]
  • [Cites] Surg Today. 2007;37(8):698-701 [17643218.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):66-74 [10618607.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):791-5 [10702394.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):821-9 [15648083.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1134-42 [11048809.001]
  • [Cites] Br J Surg. 2003 Mar;90(3):332-9 [12594669.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14 ):2012-20 [12957455.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):889-94 [15223958.001]
  • [Cites] Ann Chir Gynaecol. 1998;87(4):278-81 [9891765.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8118-21 [11719439.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):947-57 [10895817.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):53-60 [9916918.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1692-703 [11896121.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):660-7 [12949711.001]
  • [Cites] Scand J Surg. 2003;92(3):195-9 [14582540.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1339-52 [11023095.001]
  • [Cites] Colorectal Dis. 2008 Nov;10 (9):951-2 [18294266.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S83-7 [12528778.001]
  • (PMID = 20967481.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


25. Painter JN, Tapanainen H, Somer M, Tukiainen P, Aittomäki K: A 4-bp deletion in the Birt-Hogg-Dubé gene (FLCN) causes dominantly inherited spontaneous pneumothorax. Am J Hum Genet; 2005 Mar;76(3):522-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the results of a genetic study of a large Finnish family with a dominantly inherited tendency to PSP.
  • Mutations in FLCN are also responsible for Birt-Hogg-Dubé (BHD) syndrome (a dominantly inherited disease characterized by benign skin tumors, PSP, and diverse types of renal cancer) and, rarely, are detected in sporadic renal and colorectal tumors.
  • [MeSH-minor] Base Sequence. DNA / genetics. Exons. Female. Finland. Genes, Dominant. Humans. Male. Molecular Sequence Data. Pedigree. Phenotype. Proto-Oncogene Proteins. Tumor Suppressor Proteins


26. Adler A, Roll S, Marowski B, Drossel R, Rehs HU, Willich SN, Riese J, Wiedenmann B, Rösch T, Berlin Private-Practice Gastroenterology Working Group: Appropriateness of colonoscopy in the era of colorectal cancer screening: a prospective, multicenter study in a private-practice setting (Berlin Colonoscopy Project 1, BECOP 1). Dis Colon Rectum; 2007 Oct;50(10):1628-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appropriateness of colonoscopy in the era of colorectal cancer screening: a prospective, multicenter study in a private-practice setting (Berlin Colonoscopy Project 1, BECOP 1).
  • In the diagnostic group, indications were assessed according to the current guidelines for appropriateness (American Society for Gastrointestinal Endoscopy, European Panel for the Appropriateness of Gastrointestinal Endoscopy), and the results were correlated with the percentage of relevant findings (tumors, inflammatory conditions).
  • However, the percentage of relevant inflammatory and neoplastic findings (polyps, cancer, inflammatory bowel disease, benign strictures) was only 5 to 10 percent higher in the appropriate group than in the inappropriate group.
  • [MeSH-major] Colonoscopy / utilization. Colorectal Neoplasms / diagnosis. Mass Screening / utilization. Private Practice / statistics & numerical data


27. Hompes D, Aerts R, Penninckx F, Topal B: Laparoscopic liver resection using radiofrequency coagulation. Surg Endosc; 2007 Feb;21(2):175-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eleven benign and 47 malignant lesions (mostly colorectal metastases) were resected.
  • Median number [1 (1-3)] and maximum diameter [40 mm (8-170)] of tumors as well as median tumor free margins [10 mm (1-30)] were comparable in patients undergoing LLR with (20 patients) or without (25 patients) RF-assistance.
  • Significant bleeding occurred from large hepatic vessels at major resections.
  • Significant intraoperative bleeding occurs from large hepatic vessels during major resections.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Loss, Surgical / prevention & control. Catheter Ablation / adverse effects. Catheter Ablation / methods. Female. Humans. Length of Stay. Liver Neoplasms / pathology. Liver Neoplasms / surgery. Male. Middle Aged. Postoperative Complications. Probability. Prognosis. Prospective Studies. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] HPB (Oxford). 2002;4(2):95-7 [18332932.001]
  • [Cites] J Gastrointest Surg. 2004 Feb;8(2):213-6 [15036198.001]
  • [Cites] Cancer J. 2005 Jan-Feb;11(1):52-6 [15831224.001]
  • [Cites] HPB (Oxford). 2004;6(4):222-9 [18333079.001]
  • [Cites] Tumori. 2004 Jan-Feb;90(1):32-5 [15143968.001]
  • [Cites] Am J Surg. 2005 Feb;189(2):190-4 [15720988.001]
  • [Cites] Surg Endosc. 2003 Nov;17(11):1853-4; author reply 1855 [14959742.001]
  • [Cites] Ann Chir. 2002 Mar;127(3):164-70 [11933628.001]
  • [Cites] J Am Coll Surg. 2005 Mar;200(3):472-80 [15737861.001]
  • [Cites] Hepatogastroenterology. 2003 Nov-Dec;50(54):2088-92 [14696470.001]
  • [Cites] Surg Endosc. 2005 Jul;19(7):886-91 [15920694.001]
  • [Cites] Am J Surg. 2005 Jul;190(1):43-7 [15972170.001]
  • [Cites] Surg Clin North Am. 2004 Apr;84(2):451-62 [15062655.001]
  • [Cites] Hepatogastroenterology. 2002 May-Jun;49(45):803-5 [12063994.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):326-34 [9527054.001]
  • [Cites] J Chir (Paris). 2002 Feb;139(1):25-8 [12071025.001]
  • [Cites] Br J Surg. 2003 Jun;90(6):644-6 [12808610.001]
  • [Cites] Chirurg. 2004 Jan;75(1):66-9 [14740130.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):194-6 [15622008.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):90-7 [12131090.001]
  • [Cites] Surg Endosc. 2003 Dec;17(12):1914-8 [14574547.001]
  • [Cites] Surg Endosc. 2003 Jan;17(1):23-30 [12364994.001]
  • [Cites] Arch Surg. 2003 Jul;138(7):763-9; discussion 769 [12860758.001]
  • [Cites] Ann Surg. 2002 Nov;236(5):560-3 [12409660.001]
  • [Cites] J Gastrointest Surg. 2003 Sep-Oct;7(6):797-801 [13129559.001]
  • [Cites] Eur J Surg Oncol. 2003 Apr;29(3):248-53 [12657235.001]
  • [Cites] J Surg Oncol. 1998 Oct;69(2):88-93 [9808511.001]
  • [Cites] J Gastrointest Surg. 2005 Mar;9(3):360-4 [15749597.001]
  • [Cites] HPB (Oxford). 2004;6(4):230-5 [18333080.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):753-62 [11088070.001]
  • [Cites] Ann Chir. 2002 Mar;127(3):171-4 [11933629.001]
  • [Cites] Surg Endosc. 2002 Jul;16(7):1059-63 [12165823.001]
  • [Cites] J Gastrointest Surg. 2003 Sep-Oct;7(6):777-82 [13129556.001]
  • [Cites] Surg Endosc. 2003 May;17(5):834 [15768457.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):925-6 [15702522.001]
  • [Cites] J Am Coll Surg. 2003 Feb;196(2):236-42 [12595052.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S312-7 [11821830.001]
  • [Cites] HPB (Oxford). 2004;6(4):236-46 [18333081.001]
  • (PMID = 17122980.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Poultsides G, Brown M, Orlando R 3rd: Hand-assisted laparoscopic management of liver tumors. Surg Endosc; 2007 Aug;21(8):1275-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hand-assisted laparoscopic management of liver tumors.
  • METHODS: Over a 7-year period, 28 patients with liver tumors underwent 31 hand-assisted laparoscopic operations at a tertiary care center.
  • Ablation was reserved for patients with poor functional status or limited hepatic reserve, and hand-assistance was added for laparoscopic ablation of centrally located tumors (segments 7, 8, and 4a).
  • RESULTS: The selection criteria were met by 52 patients, 6 of whom had benign lesions.
  • A group of 15 patients who had metastatic colorectal cancer treated with resection and/or ablation had a mean follow-up period of 24 months (range, 2-61 months) and a mean survival time of 36 months.
  • [MeSH-major] Hepatectomy / methods. Laparoscopy / methods. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Laparoendosc Surg. 1996 Mar;6 Suppl 1:S61-3 [8832930.001]
  • [Cites] Surg Endosc. 1995 Jun;9(6):733-5 [7482177.001]
  • [Cites] Surg Clin North Am. 2004 Apr;84(2):451-62 [15062655.001]
  • [Cites] Arch Surg. 2002 Apr;137(4):407-11; discussion 412 [11926943.001]
  • [Cites] J Am Coll Surg. 1999 Sep;189(3):291-9 [10472930.001]
  • [Cites] Surg Endosc. 2002 Sep;16(9):1363 [12235510.001]
  • [Cites] Br J Surg. 1993 Dec;80(12 ):1571-4 [8298929.001]
  • [Cites] Surg Endosc. 1996 Jul;10(7):758-61 [8662435.001]
  • [Cites] J Am Coll Surg. 1997 Jul;185(1):93-100 [9208969.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1254-62 [8608500.001]
  • [Cites] Arch Surg. 1999 May;134(5):477-85; discussion 485-6 [10323419.001]
  • [Cites] J Gastrointest Surg. 2000 Jan-Feb;4(1):34-43 [10631360.001]
  • [Cites] Arch Surg. 2000 Jul;135(7):854-9 [10896382.001]
  • [Cites] Arch Surg. 1997 May;132(5):505-10; discussion 511 [9161393.001]
  • [Cites] Ann Surg. 2000 May;231(5):715-23 [10767793.001]
  • (PMID = 17479339.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


29. Todaro L, Christiansen S, Varela M, Campodónico P, Pallotta MG, Lastiri J, Sacerdote de Lustig E, Bal de Kier Joffé E, Puricelli L: Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J Neurooncol; 2007 Jun;83(2):135-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors.
  • We studied by Western blot the pattern of serum NCAM bands in patients with gliomas (n = 34), with brain metastasis of different primary cancers (n = 27) and with benign brain tumors (n = 22)] compared with healthy controls (n = 69).
  • A similar pattern was found in patients with brain metastasis or brain benign tumors, suggesting that the pattern of serum NCAM bands would be useful to detect brain tumor pathology.
  • Interestingly, we found that 9/12 patients with glioma showed a significant decrease in NCAM HMW/LMW ratio between 1-3 months after successful tumor removal.
  • Thus, serum NCAM could be a useful marker for monitoring treatment.NCAM expression was also analyzed at tissular level in 59 glioma sections from paraffined tumors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Glioma / metabolism. Neural Cell Adhesion Molecules / metabolism
  • [MeSH-minor] Adult. Aged. Brain / metabolism. Case-Control Studies. Female. Gene Expression Profiling. Humans. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Melanoma / metabolism. Melanoma / secondary. Middle Aged. Protein Isoforms. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Statistics, Nonparametric. Survival Analysis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1267-76 [9777989.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):217-28 [15674479.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):106-10 [9662259.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1991 Summer;3(3):330-3 [1821250.001]
  • [Cites] Prostate. 1997 Aug 1;32(3):214-20 [9254901.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Brain Res Mol Brain Res. 1999 Dec 10;74(1-2):69-82 [10640677.001]
  • [Cites] J Neurochem. 1989 Nov;53(5):1372-8 [2795005.001]
  • [Cites] Surgery. 2001 Nov;130(5):834-43 [11685193.001]
  • [Cites] Int J Dev Neurosci. 1993 Oct;11(5):681-90 [8116479.001]
  • [Cites] Int J Cancer. 1994 Jul 1;58(1):116-22 [8014007.001]
  • [Cites] Pancreas. 2001 Mar;22(2):122-5 [11249065.001]
  • [Cites] Int J Colorectal Dis. 2005 Jan;20(1):57-61 [15309466.001]
  • [Cites] Semin Cell Biol. 1992 Jun;3(3):189-97 [1623208.001]
  • [Cites] J Neurosci Res. 1995 May 1;41(1):49-64 [7674377.001]
  • [Cites] J Neurooncol. 2001 Feb;51(3):245-64 [11407596.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):2020-8 [9581848.001]
  • [Cites] Int J Dev Neurosci. 2000 Apr-Jun;18(2-3):193-9 [10715574.001]
  • [Cites] J Clin Pathol. 2005 Sep;58(9):978-80 [16126882.001]
  • [Cites] Neuropathol Appl Neurobiol. 1991 Jun;17(3):207-17 [1891065.001]
  • [Cites] J Cell Sci. 2002 Jan 15;115(Pt 2):283-92 [11839780.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1227-30 [9137477.001]
  • [Cites] Cell. 1988 Dec 23;55(6):955-64 [3203385.001]
  • [Cites] Br J Haematol. 2005 May;129(4):539-41 [15877737.001]
  • [Cites] J Zhejiang Univ Sci B. 2005 Jan;6(1):4-10 [15593384.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6364-70 [2400996.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38305-16 [16172115.001]
  • [Cites] J Neurosci Res. 1999 Jan 1;55(1):99-106 [9890438.001]
  • [Cites] Front Biosci. 2003 May 01;8:d900-11 [12700044.001]
  • [Cites] Prog Neurobiol. 1998 Aug;55(6):659-69 [9670224.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:425-56 [9442880.001]
  • [Cites] Curr Opin Oncol. 2004 Nov;16(6):607-13 [15627025.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):485-94 [16212813.001]
  • [Cites] Neuroimmunomodulation. 1997 Mar-Apr;4(2):57-61 [9483195.001]
  • [Cites] Histol Histopathol. 2003 Jan;18(1):207-16 [12507300.001]
  • [Cites] Oncology. 2005;69 Suppl 1:14-6 [16210871.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):415-21 [10821486.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(20):6942-6 [3863135.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):125-8 [12086870.001]
  • [Cites] Neurobiol Dis. 2004 Mar;15(2):387-93 [15006709.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):44-51 [11550301.001]
  • [Cites] Glycobiology. 2005 Sep;15(9):887-94 [15872150.001]
  • [Cites] Biol Psychiatry. 1998 May 1;43(9):680-6 [9583002.001]
  • [Cites] Acta Neurol Belg. 2004 Dec;104(4):148-53 [15742604.001]
  • [Cites] Cancer. 1998 May 15;82(10):1921-31 [9587126.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jan;65(1):1-11 [16410743.001]
  • (PMID = 17216340.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neural Cell Adhesion Molecules; 0 / Protein Isoforms
  •  go-up   go-down


30. Issakov J, Jiveliouk I, Nachmany I, Klausner J, Merimsky O: A histopathological review of gastrointestinal related mesenchymal tumors: the hidden GIST. Isr Med Assoc J; 2007 Nov;9(11):810-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A histopathological review of gastrointestinal related mesenchymal tumors: the hidden GIST.
  • BACKGROUND: The diagnosis of gastrointestinal stromal tumors is based on documentation of c-KIT and platelet-derived growth factor-alpha receptors or specific c-KIT mutations.
  • Before the diagnosis of GIST was possible, all cases had been classified as sarcomas or benign tumors.
  • OBJECTIVES: To identify cases of GIST formerly diagnosed as abdominal or retroperitoneal mesenchymal tumors.
  • METHODS: We reviewed the archive material on all surgical cases diagnosed as gastrointestinal related malignant mesenchymal tumors or GIST in our medical center during the last decade (1995-2004).
  • Thirty-eight were reconfirmed to be GIST, 19 were newly diagnosed as GIST (the hidden cases), 8 cases were re-diagnosed as mesenchymal tumors, and 3 cases of sarcoma remained sarcomas.
  • Of all the GIST tumors, c-KIT-positive and PDGFRalpha-positive tumors were more characteristic of primary gastric tumors, while c-KIT-positive and PDGFRalpha-negative tumors were found in the colorectal area.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18085040.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


31. Tamura H, Ohtsuka M, Washiro M, Kimura F, Shimizu H, Yoshidome H, Kato A, Seki N, Miyazaki M: Reg IV expression and clinicopathologic features of gallbladder carcinoma. Hum Pathol; 2009 Dec;40(12):1686-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regenerating islet-derived family, member 4 (Reg IV) has been shown to be associated with colorectal carcinogenesis and gastric carcinogenesis through intestinal metaplasia.
  • Before surgical resection, 4 (33%) of 12 patients with gallbladder carcinoma had high serum Reg IV levels, whereas Reg IV was never elevated in 12 patients with benign diseases.
  • The serum levels of Reg IV decreased after surgical resection of the tumors.
  • The serum level of Reg IV may be of use or indicative of neoplasia.
  • [MeSH-major] Adenocarcinoma / metabolism. Gallbladder Neoplasms / metabolism. Lectins, C-Type / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Enzyme-Linked Immunosorbent Assay. Gene Expression. Homeodomain Proteins / biosynthesis. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Metaplasia / genetics. Metaplasia / metabolism. Metaplasia / pathology. Neoplasm Staging. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716164.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Lectins, C-Type; 0 / REG4 protein, human
  •  go-up   go-down


32. Koukoutsis I, Pappas A, Karanikas G, Kotzadimitriou K, Chrysikos J, Tzika S, Koronakis N, Karavitis G, Lagoudianakis E, Manouras A: Desmoid tumor of the supraclavicular region: a case report. Cases J; 2009;2:7222
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoid tumor of the supraclavicular region: a case report.
  • Desmoid tumors are rare, benign fibroblastic tumors that are locally infiltrative and can cause extensive morbidity by destruction of adjacent vital structures.
  • Due to the rarity of these tumors, evidence regarding optimal treatment protocols is drawn from case reports and single-arm series with small patient numbers.
  • We report a case of a patient with a desmoid tumor of the left supraclavicular region that was diagnosed and treated in our department and a review of the current literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1390-7 [12663732.001]
  • [Cites] Am J Surg Pathol. 1977 Sep;1(3):255-70 [920873.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1517-23 [10738207.001]
  • [Cites] J Surg Oncol. 2008 May 1;97(6):554-8 [18425778.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4642-60 [17008706.001]
  • [Cites] Orthop Clin North Am. 2006 Jan;37(1):53-63 [16311111.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):158-67 [10458229.001]
  • [Cites] Am J Clin Oncol. 1998 Dec;21(6):584-90 [9856660.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):637-45 [9486614.001]
  • [Cites] Br J Surg. 1996 Nov;83(11):1494-504 [9014661.001]
  • [Cites] Int J Colorectal Dis. 1996;11(4):157-62 [8876270.001]
  • [Cites] Arch Surg. 1989 Feb;124(2):191-6 [2916941.001]
  • [Cites] J Bone Joint Surg Am. 1984 Dec;66(9):1369-74 [6501332.001]
  • [Cites] Am J Clin Pathol. 1982 Jun;77(6):665-73 [7091046.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):181-90 [12562642.001]
  • (PMID = 19829936.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2740207
  •  go-up   go-down


33. Glasgow SC, Birnbaum EH, Lowney JK, Fleshman JW, Kodner IJ, Mutch DG, Lewin S, Mutch MG, Dietz DW: Retrorectal tumors: a diagnostic and therapeutic challenge. Dis Colon Rectum; 2005 Aug;48(8):1581-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrorectal tumors: a diagnostic and therapeutic challenge.
  • PURPOSE: Tumors occurring in the retrorectal space are heterogeneous and uncommon.
  • This study examined the diagnosis, treatment, and outcome of retrorectal tumors at a tertiary referral center.
  • METHODS: Patients with primary, extramucosal neoplasms occurring in the retrorectal space were identified using a prospectively maintained, procedural database of all adult colorectal surgical patients (1981-2003).
  • Exclusion criteria included inflammatory processes, locally advanced colorectal cancer, and metastatic malignancy.
  • RESULTS: Thirty-four patients with retrorectal tumors were treated.
  • Malignant tumors comprised 21 percent.
  • Accuracy of magnetic resonance vs. computed tomographic imaging for specific histologic tumor type was 28 vs. 18 percent, respectively.
  • All benign tumors were resected with normal histologic margins and none recurred (median follow-up, 22 months).
  • CONCLUSIONS: Retrorectal tumors remain a diagnostic and therapeutic challenge.
  • Various imaging modalities are useful for planning resection but cannot establish a definitive diagnosis.
  • Whereas benign retrorectal tumors can be completely resected, curative resection of malignant retrorectal tumors remains difficult.
  • [MeSH-major] Rectal Neoplasms / diagnosis
  • [MeSH-minor] Abdomen / surgery. Adult. Age Factors. Aged. Aged, 80 and over. Blood Loss, Surgical. Blood Transfusion. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Perineum / surgery. Proctoscopy. Prospective Studies. Rectum / surgery. Retrospective Studies. Sex Factors. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15937630.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Pickhardt PJ, Kim DH, Meiners RJ, Wyatt KS, Hanson ME, Barlow DS, Cullen PA, Remtulla RA, Cash BD: Colorectal and extracolonic cancers detected at screening CT colonography in 10,286 asymptomatic adults. Radiology; 2010 Apr;255(1):83-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal and extracolonic cancers detected at screening CT colonography in 10,286 asymptomatic adults.
  • PURPOSE: To retrospectively determine the detection rates, clinical stages, and short-term patient survival for all unsuspected cancers identified at screening computed tomographic (CT) colonography, including both colorectal carcinoma (CRC) and extracolonic malignancies.
  • MATERIALS AND METHODS: From April 2004 through March 2008, prospective colorectal and extracolonic interpretation was performed in 10,286 outpatient adults (5388 men, 4898 women; mean age, 59.8 years) undergoing screening CT colonography at two centers in this institutional review board-approved, HIPAA-compliant study.
  • Benign neoplasms (including advanced colorectal adenomas), symptomatic lesions, and tumors without pathologic proof were excluded.
  • Extracolonic malignancies included renal cell carcinoma (n = 11), lung cancer (n = 8), non-Hodgkin lymphoma (n = 6), and a variety of other tumors (n = 11).
  • [MeSH-major] Colonography, Computed Tomographic. Colorectal Neoplasms / diagnostic imaging
  • [MeSH-minor] Adenoma / diagnostic imaging. Adenoma / pathology. Female. Humans. Kidney Neoplasms / diagnostic imaging. Kidney Neoplasms / pathology. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / pathology. Lymphatic Metastasis. Lymphoma, Non-Hodgkin / diagnostic imaging. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Neoplasms, Multiple Primary / diagnostic imaging. Neoplasms, Multiple Primary / pathology. Radiographic Image Interpretation, Computer-Assisted. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2010
  • (PMID = 20308446.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA144835
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


35. Falguières T, Maak M, von Weyhern C, Sarr M, Sastre X, Poupon MF, Robine S, Johannes L, Janssen KP: Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool. Mol Cancer Ther; 2008 Aug;7(8):2498-508
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool.
  • The targeting of solid tumors requires delivery tools that resist intracellular and extracellular inactivation, and that are taken up specifically by tumor cells.
  • We have shown previously that the recombinant nontoxic B-subunit of Shiga toxin (STxB) can serve as a delivery tool to target digestive tumors in animal models.
  • The aim of this study was to expand these experiments to human colorectal cancer.
  • Tissue samples of normal colon, benign adenomas, colorectal carcinomas, and liver metastases from 111 patients were obtained for the quantification of the expression of the cellular STxB receptor, the glycosphingolipid globotriaosyl ceramide (Gb(3) or CD77).
  • We found that compared with normal tissue, the expression of Gb(3) was strongly increased in colorectal adenocarcinomas and their metastases, but not in benign adenomas.
  • Of a given tumor sample, on average, 80% of the cells could visibly bind STxB, and upon incubation at 37 degrees C, STxB was transported to the Golgi apparatus, following the retrograde route.
  • This STxB-specific intracellular targeting allows the molecule to avoid recycling and degradation, and STxB could consequently be detected on tumor cells even 5 days after initial uptake.
  • In conclusion, the targeting properties of STxB could be diverted for the delivery of contrast agents to human colorectal tumors and their metastases, whose early detection and specific targeting remains one of the principal challenges in oncology.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / biosynthesis. Colorectal Neoplasms / therapy. Intestines / microbiology. Shiga Toxins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromatography, Thin Layer. Female. Humans. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Trihexosylceramides / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18687997.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Gb3 antigen; 0 / Shiga Toxins; 0 / Trihexosylceramides; 0 / stxB toxin; 71965-57-6 / globotriaosylceramide
  •  go-up   go-down


36. Pulitzer M, Xu R, Suriawinata AA, Waye JD, Harpaz N: Microcarcinoids in large intestinal adenomas. Am J Surg Pathol; 2006 Dec;30(12):1531-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcarcinoids in large intestinal adenomas.
  • Composite adenoma-carcinoid tumors are rare colorectal lesions consisting of intermingled adenomatous and carcinoid components.
  • Unlike other mixed endocrine-glandular colorectal neoplasms, which are generally malignant, their glandular component is histologically benign and their natural history is favorable.
  • The patients' clinical course was benign on the basis of 2 years' median follow-up (range, 6 mo to 10 y).
  • Two patients with incomplete polypectomies underwent hemicolectomy revealing no residual endocrine neoplasia.
  • Awareness of microcarcinoids in colonic adenomas should help avert potential diagnostic pitfalls posed by their pleomorphism, basal location, and infiltrative patterns, and may help clarify their natural history and possible relationship to composite glandular-carcinoid tumors.
  • [MeSH-major] Adenoma / pathology. Carcinoid Tumor / pathology. Intestinal Neoplasms / pathology. Intestine, Large / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Female. Humans. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122508.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Lewis MR, Deavers MT, Silva EG, Malpica A: Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge. Am J Surg Pathol; 2006 Feb;30(2):177-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge.
  • Ovarian involvement by metastatic colorectal adenocarcinoma, although not an uncommon occurrence, remains a diagnostic challenge.
  • The gross and histologic features of such metastases overlap those of primary ovarian epithelial neoplasms such as endometrioid or mucinous adenocarcinoma.
  • The clinical and pathologic features of 86 cases of metastatic colorectal adenocarcinoma involving the ovary were reviewed.
  • Presenting symptoms included abdominal or pelvic pain (45 cases), rectal bleeding (13 cases), change in bowel habits (20 cases), and vaginal bleeding (5 cases).
  • Many involved ovaries featured smooth capsules without gross evidence of surface involvement by tumor.
  • In general, the tumors had typical histologic features of metastatic colorectal adenocarcinoma, including a garland pattern and dirty necrosis.
  • In 23 cases, foci with a benign or low malignant potential appearance were seen.
  • Immunohistochemical studies showed that 29 of 29 tumors (100%) were positive for CK20; focal CK7 positivity was seen in 5 of 30 cases (17%).
  • Metastatic colorectal adenocarcinoma should be considered in the differential diagnosis of an ovarian mass, even if the mass is large and unilateral or in a young patient, to secure proper treatment of these patients.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434891.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


38. Chiang JM, Lin YS: Tumor spectrum of adult intussusception. J Surg Oncol; 2008 Nov 1;98(6):444-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor spectrum of adult intussusception.
  • Most general and colorectal surgeons are unfamiliar with its etiology and optimal management.
  • Data related to presentation, diagnosis, treatment, and pathology were analyzed.
  • Neoplasm was identified as the cause of intussusception in 66 (92%) cases, and 6 (8%) were idiopathic.
  • Lipoma (15 of 40 patients, 38%) and Peutz-Jegher adenoma (10 of 40 patients, 25%) were the two most common lesions of benign small bowel neoplasms while 27% (3 of 11) of malignant enteric intussusception cases were malignant lymphoma and metastatic respectively.
  • CONCLUSION: Lipoma is the most common benign tumor in both small and large bowel intussusception.
  • Whereas 80% of tumors associated with small bowel intussusception were benign, two-thirds of colonic intussusceptions had resulted from primary adenocarcinoma.
  • [MeSH-major] Intestinal Diseases / etiology. Intestinal Neoplasms / complications. Intussusception / etiology
  • [MeSH-minor] Abdominal Pain / etiology. Adenocarcinoma / complications. Adenoma / complications. Adolescent. Adult. Aged. Aged, 80 and over. Cystadenocarcinoma, Mucinous / complications. Female. Humans. Lipoma / complications. Lymphoma, Large B-Cell, Diffuse / complications. Male. Middle Aged. Peutz-Jeghers Syndrome / complications. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [ErratumIn] J Surg Oncol. 2009 Jun 1;99(7):457
  • (PMID = 18668640.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Levin TG, Powell AE, Davies PS, Silk AD, Dismuke AD, Anderson EC, Swain JR, Wong MH: Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract. Gastroenterology; 2010 Dec;139(6):2072-2082.e5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: CD166 (also called activated leukocyte cell adhesion molecule [ALCAM]) is a marker of colorectal cancer (CRC) stem cells; it is expressed by aggressive tumors.
  • Although the presence of CD166 at the tumor cell surface has been correlated with shortened survival, little is known about its function and expression in normal intestinal epithelia.
  • Human and mouse intestinal tumors were also analyzed.
  • RESULTS: CD166 was expressed on the surface of epithelial cells within the stem cell niche and along the length of the intestine; expression was conserved across species.
  • In the small intestine, CD166 was observed on crypt-based Paneth cells and intervening crypt-based columnar cells (putative stem cells).
  • CD166 was located in the cytoplasm and at the surface of cells within human CRC tumors.
  • CD166-positive cells were also detected in benign adenomas in mice; rare cells coexpressed CD166 and CD44 or epithelial-specific antigen.
  • CD166-positive cells appear at multiple stages of intestinal carcinoma progression, including benign and metastatic tumors.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [Cites] J Exp Med. 1995 Jun 1;181(6):2213-20 [7760007.001]
  • [Cites] Differentiation. 2003 Jan;71(1):28-41 [12558601.001]
  • [Cites] Am J Pathol. 1998 Mar;152(3):805-13 [9502422.001]
  • [Cites] J Bone Miner Res. 1998 Apr;13(4):655-63 [9556065.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):895-902 [14737120.001]
  • [Cites] Eur J Immunol. 2004 Apr;34(4):930-40 [15048703.001]
  • [Cites] J Clin Pathol. 2004 Nov;57(11):1160-4 [15509676.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Exp Cell Res. 1992 Nov;203(1):91-9 [1426054.001]
  • [Cites] J Biol Chem. 1993 Aug 25;268(24):18345-58 [8349710.001]
  • [Cites] J Neurobiol. 1994 Jul;25(7):831-45 [8089660.001]
  • [Cites] J Exp Med. 1995 Apr 1;181(4):1563-8 [7535342.001]
  • [Cites] J Cell Biol. 1998 May 4;141(3):765-77 [9566975.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55315-23 [15496415.001]
  • [Cites] J Cell Sci. 2005 Apr 1;118(Pt 7):1515-25 [15769845.001]
  • [Cites] Oncology. 2005;68(4-6):462-70 [16024937.001]
  • [Cites] Nature. 2006 Jan 5;439(7072):84-8 [16397499.001]
  • [Cites] J Clin Pathol. 2006 Apr;59(4):403-9 [16484444.001]
  • [Cites] FEBS Lett. 2006 May 15;580(11):2637-45 [16650408.001]
  • [Cites] J Immunol. 2006 Jul 15;177(2):877-84 [16818742.001]
  • [Cites] Med Sci Monit. 2006 Aug;12(8):BR263-73 [16865058.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):102-7 [17143262.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Development. 2007 Apr;134(8):1491-7 [17344225.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63 [17548814.001]
  • [Cites] Mol Cancer Ther. 2007 Oct;6(10):2737-46 [17938267.001]
  • [Cites] Nature. 2007 Oct 25;449(7165):1003-7 [17934449.001]
  • [Cites] Science. 2008 Jan 18;319(5861):336-9 [18202291.001]
  • [Cites] Nat Immunol. 2008 Feb;9(2):137-45 [18157132.001]
  • [Cites] Nat Cell Biol. 2008 Mar;10(3):353-60 [18264089.001]
  • [Cites] Stem Cells. 2008 Mar;26(3):630-7 [18055444.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1726-33 [18347173.001]
  • [Cites] Cell Death Differ. 2008 Jun;15(6):947-58 [18259194.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):48-53 [18356041.001]
  • [Cites] PLoS One. 2008;3(6):e2428 [18560594.001]
  • [Cites] Nat Genet. 2008 Jul;40(7):915-20 [18536716.001]
  • [Cites] BMC Gastroenterol. 2008;8:57 [19055726.001]
  • [Cites] Cell. 2009 Mar 6;136(5):903-12 [19269367.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3382-9 [19336570.001]
  • [Cites] Cell Stem Cell. 2009 May 8;4(5):427-39 [19427292.001]
  • [Cites] Nature. 2009 May 14;459(7244):262-5 [19329995.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2010 May;298(5):G590-600 [20185687.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):769-74 [10702391.001]
  • [Cites] Cancer Metastasis Rev. 2000;19(3-4):I-XI, 193-383 [11394186.001]
  • [Cites] Blood. 2001 Oct 1;98(7):2134-42 [11568000.001]
  • [Cites] J Exp Med. 2002 Jun 17;195(12):1549-63 [12070283.001]
  • [Cites] Prostate. 2003 Jan 1;54(1):34-43 [12481253.001]
  • [Cites] Blood. 1997 Apr 15;89(8):2706-16 [9108388.001]
  • (PMID = 20826154.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA118235; United States / NIDDK NIH HHS / DK / U01 DK085525-02; United States / NHLBI NIH HHS / HL / T32 HL007781; United States / NCI NIH HHS / CA / CA106195-06A1; United States / NCI NIH HHS / CA / CA118235-05; United States / NICHD NIH HHS / HD / T32 HD049309-05; United States / NCI NIH HHS / CA / CA106195; United States / NCI NIH HHS / CA / T32 CA106195; United States / NICHD NIH HHS / HD / HD049309; United States / NICHD NIH HHS / HD / T32 HD049309; United States / NCI NIH HHS / CA / T32 CA106195-06A1; United States / NHLBI NIH HHS / HL / T32 HL007781-14; United States / NIDDK NIH HHS / DK / R01 DK068326; United States / NCI NIH HHS / CA / CA118235; United States / NIDDK NIH HHS / DK / R01 DK068326-05; United States / NIDDK NIH HHS / DK / DK068326; United States / NIDDK NIH HHS / DK / DK085525-02; United States / NICHD NIH HHS / HD / HD049309-05; United States / NHLBI NIH HHS / HL / HL007781-14; United States / NHLBI NIH HHS / HL / HL007781; United States / NIDDK NIH HHS / DK / U01 DK085525; United States / NIDDK NIH HHS / DK / DK085525; United States / NIDDK NIH HHS / DK / DK068326-05; United States / NCI NIH HHS / CA / R01 CA118235-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ALCAM protein, human; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules, Neuronal; 0 / Fetal Proteins
  • [Other-IDs] NLM/ NIHMS234467; NLM/ PMC2997177
  •  go-up   go-down


40. Cserni G, Bori R, Sejben I: Vascular invasion demonstrated by elastic stain-a common phenomenon in benign granular cell tumors. Virchows Arch; 2009 Feb;454(2):211-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular invasion demonstrated by elastic stain-a common phenomenon in benign granular cell tumors.
  • Granular cell tumor is generally benign, but rare malignant cases have been documented.
  • Features of malignancy include necrosis, cellular spindling, vesicular nuclei with large nucleoli, increased mitotic activity, high nuclear to cytoplasmic ratio, and pleomorphism, but not vascular invasion.
  • Venous invasion was incidentally identified with the orcein elastic stain in an otherwise benign granular cell tumor (propositus case).
  • Four further benign granular cell tumors were also analyzed; venous invasion was discovered in three.
  • It is suggested that vascular invasion is not uncommon in granular cell tumors and should not lead to the classification of the tumor as malignant or atypical.
  • It is also suggested that some cases of vascular invasion identified by elastic stains in tumors such as colorectal carcinomas (where these stains are recommended for routine use) may also represent invasion of vascular structures without the propensity of metastasis.
  • [MeSH-major] Blood Vessels / pathology. Elastic Tissue / pathology. Granular Cell Tumor / pathology. Staining and Labeling / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2007 Nov;50(11):1867-72 [17665249.001]
  • [Cites] Hum Pathol. 2005 Mar;36(3):291-8 [15791574.001]
  • [Cites] Histopathology. 2006 Nov;49(5):487-92 [17064294.001]
  • [Cites] Minerva Stomatol. 2006 Jul-Aug;55(7-8):423-30 [17041542.001]
  • [Cites] Arch Pathol Lab Med. 2005 Nov;129(11):1465-9 [16253028.001]
  • [Cites] Cancer. 1996 Dec 1;78(11):2313-7 [8941000.001]
  • [Cites] Am J Surg Pathol. 2008 Apr;32(4):560-5 [18300797.001]
  • [Cites] J Pathol. 1976 Jan;118(1):9-16 [1255302.001]
  • [Cites] Histopathology. 2006 Aug;49(2):107-20 [16879388.001]
  • [Cites] J Clin Pathol. 2004 Jul;57(7):769-72 [15220375.001]
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):779-94 [9669341.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):208-11 [8119722.001]
  • [Cites] Adv Anat Pathol. 1999 Jul;6(4):186-203 [10410172.001]
  • [Cites] Am J Clin Pathol. 1985 Apr;83(4):426-30 [3984936.001]
  • [Cites] Am J Surg Pathol. 1985 Feb;9(2):125-8 [3919599.001]
  • [Cites] AJR Am J Roentgenol. 1999 Nov;173(5):1303-13 [10541110.001]
  • (PMID = 19066954.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


41. Shi X, Gong E, Wu X: Alpha-methylacyl-CoA racemase/P504S overexpression in colorectal carcinoma is correlated with tumor differentiation. Appl Immunohistochem Mol Morphol; 2007 Jun;15(2):175-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-methylacyl-CoA racemase/P504S overexpression in colorectal carcinoma is correlated with tumor differentiation.
  • Little is known about correlation of AMACR expression with colorectal carcinoma (CRC) differentiation and prognosis.
  • These cases were divided into 3 groups according to the histologic differentiation of the primary tumors. group A included 50 cases of histologically well and moderately differentiated CRCs, 20 of these with lymph node metastasis; group B included 23 cases of well and moderately differentiated CRCs, histologically similar to group A, except these tumors had small foci (less than 20%) of high-grade carcinoma, and 10 of these had lymph node metastasis; group C included 33 cases of poorly differentiated adenocarcinoma and undifferentiated carcinoma, 17 with lymph node metastasis.
  • In group B, although overexpression of AMACR in primary tumors was similar to that of group A, it was only seen in 30.0% of group B metastatic tumors, which was similar to the rate of expression in group C (23.5%).
  • In contrast, rates of expression in group A primary and metastatic tumors were similar (80.0% and 75.0%).
  • Positive staining for AMACR in benign epithelium adjacent to tumor was rare (<2%).
  • Our findings support the view that the expression of AMACR in CRC is correlated with tumor differentiation.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525630.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


42. Modlin IM, Kidd M, Latich I, Zikusoka MN, Eick GN, Mane SM, Camp RL: Genetic differentiation of appendiceal tumor malignancy: a guide for the perplexed. Ann Surg; 2006 Jul;244(1):52-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic differentiation of appendiceal tumor malignancy: a guide for the perplexed.
  • OBJECTIVE: To use differential gene expression of candidate markers to discriminate benign appendiceal carcinoids (APCs) from malignant and mixed cell APCs.
  • SUMMARY BACKGROUND DATA: Controversy exists in regard to the appropriate surgical management of APCs since it is sometimes difficult to predict tumor behavior using traditional pathologic criteria.
  • METHODS: Total RNA was isolated using TRIzol reagent from 42 appendiceal samples, including appendiceal carcinoids identified at exploration for appendicitis (no evidence of metastasis; n = 16), appendicitis specimens (n = 11), malignant appendiceal tumors (> 1.5 cm, evidence of metastatic invasion; n = 7), and mixed (goblet) cell appendiceal adenocarcinoids (n = 3), normal appendiceal tissue (n = 5), and 5 colorectal cancers.
  • RESULTS: CgA message was elevated (> 1000-fold, P < 0.05) in all tumor types.
  • MAGE-D2 and MTA1 message were significantly elevated (> 10-fold, P < 0.01) in the malignant and goblet cell adenocarcinoid tumors but not in the appendicitis-associated carcinoids or normal mucosa.
  • Elevated CgA transcript and protein levels indicative of a carcinoid tumor were identified in one acute appendicitis sample with no histologic evidence of a tumor.
  • CgA identified all appendiceal tumors as well as covert lesions, which may be more prevalent than previously recognized.
  • The molecular delineation of malignant appendiceal tumor potential provides a scientific basis to define the appropriate surgical management as opposed to morphologic assessment alone.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 1999 Sep 13;159(16):1841-5 [10493314.001]
  • [Cites] Am J Gastroenterol. 1998 Mar;93(3):422-8 [9517651.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):229-36 [15599934.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1717-51 [15887161.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):273-80 [16432362.001]
  • [Cites] Ann Surg Oncol. 2006 Feb;13(2):253-62 [16424981.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1480-8 [16502410.001]
  • [Cites] Digestion. 2000;62 Suppl 1:33-8 [10940685.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):419-29 [11159180.001]
  • [Cites] J Clin Pathol. 2001 Apr;54(4):257-71 [11304841.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1821-9 [11920546.001]
  • [Cites] Mod Pathol. 2002 Jun;15(6):599-605 [12065772.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3307-12 [12115365.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):863-72 [12131153.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1323-7 [12389040.001]
  • [Cites] Pathol Oncol Res. 2002;8(3):204-19 [12516003.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Exp Mol Pathol. 2003 Jun;74(3):336-40 [12782023.001]
  • [Cites] Eur J Surg Oncol. 2003 Oct;29(8):682-8 [14511618.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):585-603 [14567019.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1317-22 [14598408.001]
  • [Cites] Mod Pathol. 2003 Dec;16(12):1189-98 [14681318.001]
  • [Cites] Acta Oncol. 2003;42(7):672-92 [14690153.001]
  • [Cites] Biotechnol Bioeng. 2003 Dec 30;84(7):822-33 [14708123.001]
  • [Cites] Int J Oncol. 2004 Feb;24(2):305-12 [14719106.001]
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):163-9 [15043285.001]
  • [Cites] Int J Cancer. 2004 Jun 20;110(3):362-7 [15095300.001]
  • [Cites] Hum Pathol. 2004 Apr;35(4):424-9 [15116322.001]
  • [Cites] Am Surg. 2004 Jul;70(7):593-9 [15279181.001]
  • [Cites] Surg Endosc. 2004 Jul;18(7):1063-6 [15156378.001]
  • [Cites] Digestion. 1986;35 Suppl 1:3-22 [3539679.001]
  • [Cites] Acta Oncol. 1989;28(3):325-9 [2545231.001]
  • [Cites] N Engl J Med. 1992 Oct 29;327(18):1285-8 [1406819.001]
  • [Cites] Biochem J. 1994 Jan 15;297 ( Pt 2):389-97 [8297347.001]
  • [Cites] J Biol Chem. 1994 Sep 16;269(37):22958-63 [8083195.001]
  • [Cites] Gene. 1995 Jun 14;159(1):97-104 [7607577.001]
  • [Cites] Int J Cancer. 1997 Aug 22;74(4):459-63 [9291440.001]
  • [Cites] Dis Colon Rectum. 1998 Jan;41(1):75-80 [9510314.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):266-70 [15551742.001]
  • (PMID = 16794389.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA097050; United States / NCI NIH HHS / CA / R01-CA-097050
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, Neoplasm; 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Chromogranin A; 0 / Chromogranins; 0 / Genetic Markers; 0 / MAGED2 protein, human; 0 / NAP1L1 protein, human; 0 / NLRP1 protein, human; 0 / Nuclear Proteins; 0 / Nucleosome Assembly Protein 1; 0 / Repressor Proteins; EC 3.5.1.- / Mta1 protein, human; EC 3.5.1.98 / Histone Deacetylases
  • [Other-IDs] NLM/ PMC1570599
  •  go-up   go-down


43. Dultz LA, Ullery BW, Sun HH, Huston TL, Eachempati SR, Barie PS, Shou J: Ileocecal valve lipoma with refractory hemorrhage. JSLS; 2009 Jan-Mar;13(1):80-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Lipomas are the most common benign mesenchymal tumors of the gastrointestinal tract, with the colon being the most prevalent site.
  • Tumors >2 cm in diameter may occasionally cause nonspecific symptoms, including change in bowel habits, abdominal pain, or rectal bleeding, but with resection the prognosis is excellent.

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2001 May;67(5):491-4 [11379657.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Jun;14(6):701-2 [12072607.001]
  • [Cites] Am J Surg. 2003 Jul;186(1):81-2 [12842756.001]
  • [Cites] AJR Am J Roentgenol. 2003 Oct;181(4):981-5 [14500213.001]
  • [Cites] Surg Today. 2004;34(1):72-5 [14714234.001]
  • [Cites] Int J Clin Pract. 2004 Apr;58(4):424-5 [15161133.001]
  • [Cites] Int Surg. 1971 Aug;56(2):113-7 [5560000.001]
  • [Cites] Dis Colon Rectum. 1972 Nov-Dec;15(6):441-4 [4645612.001]
  • [Cites] Surg Gynecol Obstet. 1975 Oct;141(4):565-8 [1166382.001]
  • [Cites] Radiology. 1982 Feb;142(2):409-14 [7054830.001]
  • [Cites] Arch Surg. 1983 Sep;118(9):1081-3 [6615219.001]
  • [Cites] Am J Gastroenterol. 1984 Dec;79(12):964-7 [6507422.001]
  • [Cites] Dis Colon Rectum. 1987 Nov;30(11):888-93 [3677966.001]
  • [Cites] Gastrointest Endosc. 1990 Sep-Oct;36(5):435-8 [2227312.001]
  • [Cites] Eur J Surg. 1991 Jan;157(1):51-5 [1675882.001]
  • [Cites] Acta Radiol. 1995 Sep;36(5):478-80 [7640090.001]
  • [Cites] Eur J Surg. 1996 Nov;162(11):915-9 [8956963.001]
  • [Cites] Aust N Z J Surg. 1998 Feb;68(2):133-5 [9494006.001]
  • [Cites] Int J Colorectal Dis. 1998;13(1):1-2 [9548092.001]
  • [Cites] Surg Today. 2005;35(2):161-5 [15674501.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2005 Apr;15(2):173-5 [15898912.001]
  • [Cites] Acta Gastroenterol Belg. 2005 Apr-Jun;68(2):280-2 [16013653.001]
  • [Cites] JSLS. 2005 Jul-Sep;9(3):342-4 [16121884.001]
  • [Cites] MedGenMed. 2005;7(1):16 [16369321.001]
  • [Cites] Rom J Gastroenterol. 2005 Dec;14(4):393-6 [16400357.001]
  • [Cites] JSLS. 2006 Apr-Jun;10(2):250-3 [16882431.001]
  • [Cites] World J Gastroenterol. 2006 Aug 21;12(31):5075-7 [16937511.001]
  • [Cites] World J Gastroenterol. 2007 May 7;13(17):2510-3 [17552037.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2007 Aug;17(4):467-9 [17705728.001]
  • (PMID = 19366548.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3015905
  •  go-up   go-down


44. Arnold CN, Nagasaka T, Goel A, Scharf I, Grabowski P, Sosnowski A, Schmitt-Gräff A, Boland CR, Arnold R, Blum HE: Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors. Int J Cancer; 2008 Oct 1;123(7):1556-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors.
  • To better understand the molecular pathogenesis of neuroendocrine tumors (NET), we investigated the molecular and clinical characteristics of malignant poorly differentiated colorectal NET and compared these findings with sporadic CRC and well-differentiated benign and malignant fore-/midgut NET.
  • Tumors were analyzed and correlated for microsatellite instability (MSI) and the CpG island methylator phenotype (CIMP).
  • A total of 34 malignant poorly differentiated colorectal NET, 38 well-differentiated benign and malignant fore-/midgut-NET and 150 sporadic colorectal cancers (CRC) with known MSI status were investigated.
  • Of the 34 colorectal NET, 0/1 of the MSI-H, 3/5 (60%) of the MSI-L and 13/19 (68%) of the MSS tumors were CIMP+ (p = 0.17).
  • Of the fore-/midgut-NET, none was MSI-H. 20/34 (59%) colorectal NET vs. 11/38 (29%) fore-/midgut-NET were CIMP+ (p = 0.01).
  • The Ki-67 index was significantly higher in poorly differentiated colorectal NET compared to the less malignant fore-/midgut-NET (p < 0.0001).
  • We conclude that molecular pathogenesis in sporadic CRC and poorly differentiated colorectal NET is different despite some similarities.
  • Main differences between malignant well-differentiated and poorly differentiated NET are the Ki-67 proliferation rate and differential methylation in tumor-associated genes.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colorectal Neoplasms / genetics. Colorectal Neoplasms / mortality. Neuroendocrine Tumors / genetics. Neuroendocrine Tumors / mortality

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):947-57 [14871972.001]
  • [Cites] Int J Cancer. 2007 May 15;120(10):2157-64 [17278096.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:199-208 [15153435.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):805-15 [15459661.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3075-9 [2039987.001]
  • [Cites] Nat Med. 1996 Mar;2(3):281-2 [8612223.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2545-50 [9122232.001]
  • [Cites] Nature. 1997 Apr 10;386(6625):623-7 [9121588.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Genes Chromosomes Cancer. 1998 May;22(1):50-6 [9591634.001]
  • [Cites] Lancet. 1997 Oct 25;350(9086):1223 [9652567.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):11-6 [10389971.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):988-93 [15573120.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):855-60 [15613458.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):229-36 [15599934.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):256-60 [15842051.001]
  • [Cites] Virchows Arch. 2007 Oct;451(4):757-62 [17674042.001]
  • [Cites] Endocr Pathol. 2007 Fall;18(3):145-9 [18058263.001]
  • [Cites] Curr Opin Oncol. 2002 Jan;14(1):38-45 [11790979.001]
  • [Cites] Virchows Arch. 2002 Sep;441(3):256-63 [12242522.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 Feb;15(2):139-43 [12560757.001]
  • [Cites] Oncogene. 2003 Feb 13;22(6):924-34 [12584572.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Mar;88(3):1367-73 [12629131.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1608-14 [12670912.001]
  • [Cites] Diagn Mol Pathol. 2003 Dec;12(4):181-6 [14639103.001]
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):570-6 [10747315.001]
  • [Cites] Ann Surg. 2000 Oct;232(4):549-56 [10998653.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1097-103 [11021813.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4073-81 [11051259.001]
  • [Cites] Oncology. 2000 Sep;59(3):229-37 [11053991.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Nov;85(11):4146-56 [11095446.001]
  • [Cites] Gut. 2001 Apr;48(4):536-41 [11247899.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Apr;13(4):405-11 [11338071.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5905-10 [11479232.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1717-51 [15887161.001]
  • [Cites] Neuroendocrinology. 2005;81(1):1-9 [15809513.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Aug;3(8):761-71 [16234004.001]
  • [Cites] Int J Colorectal Dis. 2006 Apr;21(3):221-30 [16485142.001]
  • [Cites] Virchows Arch. 2006 Oct;449(4):395-401 [16967267.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):127-38 [17087942.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:13-27 [15153416.001]
  • (PMID = 18646189.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA072851; United States / NCI NIH HHS / CA / R01 CA072851-13
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS187521; NLM/ PMC2851204
  •  go-up   go-down


45. Olgac S, Hutchinson B, Tickoo SK, Reuter VE: Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma. Mod Pathol; 2006 Feb;19(2):218-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma.
  • Metanephric adenoma (MA), a well-described renal neoplasm, usually behaves in a benign fashion.
  • It may have areas that are morphologically similar to papillary renal cell carcinoma (RCC) type, or epithelial (tubular predominant) type Wilms' tumor.
  • Alpha-methylacyl-CoA racemase (AMACR), a molecular marker for prostate carcinoma, has subsequently been found to be overexpressed in breast, colorectal and ovarian cancers, among others.
  • Recent microarray analysis of renal tumors has shown an increase of AMACR mRNA levels in papillary RCC but not in other subtypes.
  • We investigated the utility of immunohistochemical staining for AMACR, cytokeratin 7(CK7), CD57 and WT1 to differentiate between the above-mentioned three neoplasms.
  • Immunohistochemical stains were performed on paraffin-embedded tissue sections from 25 papillary RCC, 10 MAs and eight Wilms' tumors.
  • AMACR was positive in one (10%) of 10 MAs and 24 (96%) of 25 papillary RCC, while it was negative in all Wilms' tumors.
  • CK7 was positive in 20 of 25 papillary RCCs, focally positive in one Wilms' tumor and was negative in all MAs.
  • CD57 was positive in all six MAs that were stained, focally positive in one of 25 papillary RCC and one of eight Wilms' tumors.
  • WT1 was positive in seven of 10 MAs, three of 25 papillary RCCs and all eight Wilms' tumors.
  • In conclusion, diffuse and strong immunoreactivity for AMACR may be useful in differentiating papillary RCC from MA but a panel which includes AMACR, CK7 and CD57 is better in this differential diagnosis.
  • AMACR is not helpful in differentiating MA from Wilms' tumor, but CD57 is helpful in this differential diagnosis.
  • WT1 may be useful in separating Wilms' tumor from MA and papillary RCC but is not helpful in differentiating MA from papillary RCC.
  • [MeSH-major] Adenoma / pathology. Biomarkers, Tumor / analysis. Kidney Neoplasms / pathology. Racemases and Epimerases / analysis
  • [MeSH-minor] Antigens, CD57 / analysis. Carcinoma, Papillary / enzymology. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / enzymology. Carcinoma, Renal Cell / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Keratin-7. Keratins / analysis. WT1 Proteins / analysis. Wilms Tumor / enzymology. Wilms Tumor / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424894.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD57; 0 / Biomarkers, Tumor; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / WT1 Proteins; 68238-35-7 / Keratins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


46. Vishnevskiĭ VA, Efanov MG, Ikramov RZ, Shevchenko TV, Melekhina OV, Kozyrin IA: [Hilar glissonean access to vascular-secretory elements in anatomical segmental liver resections]. Khirurgiia (Mosk); 2008;(9):33-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It still remains unclear which patients with hepatic tumors can favour anatomical segmental liver resections instead of major liver resection.
  • Seven patients had liver metastases of colorectal cancer, one had primary hepatic carcinoma and two had benign lesions, anatomical segmental liver resection were performed without Pringle maneuver.
  • Multiple, large and deep-embedded lesions were removed completely, with tumor-free resection margins.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833181.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


47. Groen EJ, Roos A, Muntinghe FL, Enting RH, de Vries J, Kleibeuker JH, Witjes MJ, Links TP, van Beek AP: Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol; 2008 Sep;15(9):2439-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Familial adenomatous polyposis (FAP) is an autosomal dominantly inherited disorder, which results from a germ line mutation in the APC (adenomatous polyposis coli) gene.
  • FAP is characterized by the formation of hundreds to thousands of colorectal adenomatous polyps.
  • Although the development of colorectal cancer stands out as the most prevalent complication, FAP is a multisystem disorder of growth.
  • Affected individuals can develop thyroid and pancreatic cancer, hepatoblastomas, CNS tumors (especially medulloblastomas), and various benign tumors such as adrenal adenomas, osteomas, desmoid tumors and dental abnormalities.
  • Due to improved longevity, as a result of better prevention of colorectal cancer, the risk of these clinical problems will further increase.
  • [MeSH-major] Adenomatous Polyposis Coli / diagnosis. Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 May;18(9):1967-79 [10784639.001]
  • [Cites] Mayo Clin Proc. 2000 Jun;75(6):636-7 [10852426.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21 Suppl):81S-92S [11060333.001]
  • [Cites] Dis Colon Rectum. 2000 Dec;43(12):1739-42 [11156460.001]
  • [Cites] Dis Colon Rectum. 2000 Dec;43(12):1759-62; discussion 1762-3 [11156464.001]
  • [Cites] Endocr Res. 2000 Nov;26(4):783-90 [11196455.001]
  • [Cites] Int J Cancer. 2001 Mar 20;95(2):102-7 [11241320.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):721-33 [11257105.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):429-32 [11283619.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2744-58 [9215849.001]
  • [Cites] AJR Am J Roentgenol. 1997 Aug;169(2):465-72 [9242755.001]
  • [Cites] Intern Med. 1997 Aug;36(8):536-42 [9260769.001]
  • [Cites] Int J Colorectal Dis. 1997;12(4):240-2 [9272455.001]
  • [Cites] Dis Colon Rectum. 1997 Sep;40(9):1023-8 [9293929.001]
  • [Cites] Gut. 1997 Sep;41(3):417 [9378405.001]
  • [Cites] Int J Cancer. 1998 Jan 5;75(1):162-4 [9426707.001]
  • [Cites] Ann Surg. 1998 Jan;227(1):57-62 [9445111.001]
  • [Cites] Hum Pathol. 1998 Mar;29(3):302-6 [9496836.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):286-92 [10634400.001]
  • [Cites] Scand J Gastroenterol. 1999 Dec;34(12):1230-5 [10636071.001]
  • [Cites] Science. 2000 Mar 3;287(5458):1606-9 [10733430.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):433-8 [11283620.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):332-9 [11466687.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1127-35 [11677205.001]
  • [Cites] Am J Gastroenterol. 2002 Jan;97(1):180-5 [11808944.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):55-67 [11900252.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):1941-6 [11994321.001]
  • [Cites] Gut. 2002 Sep;51(3):446-9 [12171972.001]
  • [Cites] Ann Intern Med. 2003 Mar 4;138(5):424-9 [12614096.001]
  • [Cites] Gut. 2003 May;52(5):742-6 [12692062.001]
  • [Cites] Acta Radiol. 2003 Mar;44(2):158-9 [12694100.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1698-707 [12721244.001]
  • [Cites] Lancet. 2003 May 3;361(9368):1552-4 [12737880.001]
  • [Cites] Lancet. 2003 Jun 14;361(9374):2059-67 [12814730.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):668-78 [12910509.001]
  • [Cites] Eur J Cancer. 2003 Oct;39(15):2200-4 [14522379.001]
  • [Cites] Fam Cancer. 2001;1(2):111-9 [14574007.001]
  • [Cites] Gastroenterol Clin Biol. 2003 Aug-Sep;27(8-9):818-20 [14586255.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):612-20 [14745880.001]
  • [Cites] Semin Neonatol. 2003 Oct;8(5):403-10 [15001128.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):652; author reply 653 [15274082.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):666-75 [15497120.001]
  • [Cites] Australas Ann Med. 1967 Aug;16(3):242-4 [6056613.001]
  • [Cites] Clin Genet. 1981 Jul;20(1):67-73 [7296952.001]
  • [Cites] Cancer. 1983 Mar 15;51(6):1171-5 [6129922.001]
  • [Cites] Arch Dis Child. 1983 Dec;58(12):959-62 [6318669.001]
  • [Cites] Cancer. 1985 May 1;55(9):2001-4 [3978580.001]
  • [Cites] Dis Colon Rectum. 1986 Jan;29(1):55-8 [3940808.001]
  • [Cites] N Engl J Med. 1987 Mar 12;316(11):661-7 [3821797.001]
  • [Cites] Br J Surg. 1987 May;74(5):377-80 [3036290.001]
  • [Cites] Acta Chir Scand. 1987;153(5-6):379-83 [2821714.001]
  • [Cites] Med Pediatr Oncol. 1989;17(5):441-7 [2571918.001]
  • [Cites] J Craniomaxillofac Surg. 1989 Nov;17(8):350-3 [2592575.001]
  • [Cites] J Pediatr. 1991 Nov;119(5):766-8 [1658283.001]
  • [Cites] Surgery. 1991 Dec;110(6):1014-21 [1745970.001]
  • [Cites] Hum Genet. 1992 May;89(3):298-300 [1351034.001]
  • [Cites] Am J Med Genet. 1992 Aug 1;43(6):1023-5 [1329510.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):101-8 [8382467.001]
  • [Cites] Int J Oral Maxillofac Surg. 1993 Aug;22(4):226-30 [8409564.001]
  • [Cites] Dis Colon Rectum. 1993 Nov;36(11):1059-62 [8223060.001]
  • [Cites] Gastroenterology. 1993 Nov;105(5):1550-2 [8224661.001]
  • [Cites] Gut. 1993 Oct;34(10):1394-6 [8244108.001]
  • [Cites] Gut. 1994 Mar;35(3):377-81 [8150351.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2065-8 [8156512.001]
  • [Cites] Hum Mutat. 1994;3(2):121-5 [8199592.001]
  • [Cites] J Clin Pathol. 1994 Sep;47(9):860-1 [7962661.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] AJR Am J Roentgenol. 1995 Dec;165(6):1460-1 [7484586.001]
  • [Cites] Int J Colorectal Dis. 1996;11(2):88-91 [8739833.001]
  • [Cites] Lancet. 1996 Aug 17;348(9025):433-5 [8709782.001]
  • [Cites] Int J Colorectal Dis. 1996;11(4):157-62 [8876270.001]
  • [Cites] Cancer. 1996 Dec 1;78(11):2400-10 [8941012.001]
  • [Cites] Br J Surg. 1996 Nov;83(11):1494-504 [9014661.001]
  • [Cites] Gut. 1996 Dec;39(6):867-9 [9038672.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):299-308 [9096761.001]
  • [Cites] Chirurgie. 1997;122(1):31-4 [9183898.001]
  • [Cites] World J Surg. 1998 Dec;22(12):1231-6 [9841749.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):1007-14 [9869223.001]
  • [Cites] J Med Genet. 1999 Jan;36(1):65-7 [9950370.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):350-61 [10077047.001]
  • [Cites] Dis Colon Rectum. 1999 Apr;42(4):529-32 [10215057.001]
  • [Cites] Am J Pathol. 1999 Jul;155(1):7-9 [10393829.001]
  • [Cites] Br J Surg. 1999 Sep;86(9):1185-9 [10504375.001]
  • [Cites] Am J Hum Genet. 1952 Mar;4(1):31-6 [14933371.001]
  • [Cites] Am J Hum Genet. 1953 Jun;5(2):139-47 [13065261.001]
  • [Cites] Dis Colon Rectum. 1959 Sep-Oct;2:465-8 [13839882.001]
  • [Cites] J Clin Pathol. 2005 Jan;58(1):97-101 [15623495.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1642-54 [15887156.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):273-80 [15947102.001]
  • [Cites] Fam Cancer. 2005;4(2):135-8 [15951964.001]
  • [Cites] Lancet. 2005 Jun 11-17;365(9476):2014-23 [15950715.001]
  • [Cites] J Pediatr. 2005 Aug;147(2):263-6 [16126064.001]
  • [Cites] Ned Tijdschr Tandheelkd. 2005 Sep;112(9):340-4 [16184913.001]
  • [Cites] Arch Pathol Lab Med. 2005 Nov;129(11):1398-400 [16253018.001]
  • [Cites] Pancreas. 2005 Nov;31(4):428-9 [16258383.001]
  • [Cites] Radiology. 2005 Dec;237(3):794-800 [16304103.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):385-98 [16454848.001]
  • [Cites] Gastrointest Endosc. 2006 Apr;63(4):570-80 [16564854.001]
  • [Cites] Thyroid. 2006 Feb;16(2):109-42 [16420177.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 [16682259.001]
  • [Cites] Pediatr Blood Cancer. 2006 Nov;47(6):851-4 [16106429.001]
  • [Cites] Pediatr Blood Cancer. 2006 Nov;47(6):811-8 [16317745.001]
  • [Cites] Fam Cancer. 2006;5(3):263-73 [16998672.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1258-64 [16952208.001]
  • [Cites] Horm Res. 2006;66(5):207-10 [16865001.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jun;103(6):e30-4 [17449294.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Feb;6(2):215-9 [18237870.001]
  • [CommentIn] Ann Surg Oncol. 2009 May;16(5):1446-8; author reply 1449-50 [19266242.001]
  • (PMID = 18612695.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein
  • [Number-of-references] 111
  • [Other-IDs] NLM/ PMC2518080
  •  go-up   go-down


48. Sherman ME, Lacey JV, Buys SS, Reding DJ, Berg CD, Williams C, Hartge P: Ovarian volume: determinants and associations with cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev; 2006 Aug;15(8):1550-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical studies have reported associations between ovarian stromal hyperplasia and the diagnosis of hormonally related tumors such as endometrial cancer.
  • To assess the hypothesis that characteristics of benign ovaries among postmenopausal women are related to risk for breast, endometrial, and colon cancer, we analyzed systematically collected transvaginal ultrasound data for participants enrolled in the screening arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
  • We conclude that large ovaries among postmenopausal women may represent a marker of risk for hormonally related tumors.
  • [MeSH-major] Ovarian Neoplasms / etiology. Ovary / pathology. Postmenopause
  • [MeSH-minor] Aged. Case-Control Studies. Colonic Neoplasms / etiology. Colonic Neoplasms / pathology. Endometrial Neoplasms / etiology. Endometrial Neoplasms / pathology. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16896048.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


49. Ji BT, Weissfeld JL, Chow WH, Huang WY, Schoen RE, Hayes RB: Tobacco smoking and colorectal hyperplastic and adenomatous polyps. Cancer Epidemiol Biomarkers Prev; 2006 May;15(5):897-901
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tobacco smoking and colorectal hyperplastic and adenomatous polyps.
  • Colorectal adenomas and possibly some hyperplastic polyps are precursors of colorectal cancer.
  • Tobacco use is associated in epidemiologic studies with these polyps, although links between smoking and colorectal cancer are less consistent.
  • To characterize the role of tobacco in early colorectal carcinogenesis, we compared tobacco use among 4,383 subjects with histologically verified benign (hyperplastic or adenomatous) polyps of the distal colon (descending colon, sigmoid, and rectum) with tobacco use among 33,667 subjects who were endoscopy negative for distal colon tumors, in the screening arm of the Prostate, Lung, Colorectal, and Ovarian Trial, a randomized trial of flexible sigmoidoscopy.
  • [MeSH-major] Adenomatous Polyposis Coli / etiology. Colorectal Neoplasms / etiology. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702367.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


50. Yang BL, Gu YF, Shao WJ, Chen HJ, Sun GD, Jin HY, Zhu X: Retrorectal tumors in adults: magnetic resonance imaging findings. World J Gastroenterol; 2010 Dec 14;16(46):5822-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrorectal tumors in adults: magnetic resonance imaging findings.
  • AIM: To retrospectively evaluate the magnetic resonance imaging (MRI) features of adult retrorectal tumors and compare with histopathologic findings.
  • METHODS: MRI features of 21 patients with preoperative suspicion of retrorectal tumors were analyzed based on the histopathological and clinical data.
  • RESULTS: Fourteen benign cystic lesions appeared hypointense on T1-weighted images, and hyperintense on T2-weighted images with regular peripheral rim.
  • Six solid tumors were malignant lesions and showed heterogeneous intensity on MRI.
  • Gastrointestinal stromal tumors displayed low signal intensity on T1-weighted images, and intermediate to high signal intensity on T2-weighted images.
  • CONCLUSION: MRI is a helpful technique to define the extent of the retrorectal tumor and its relationship to the surrounding structures, and also to demonstrate possible complications so as to choose the best surgical approach.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Rectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1985 Nov;28(11):855-8 [4053899.001]
  • [Cites] Eur Radiol. 2004 Oct;14(10):1926-9 [15300393.001]
  • [Cites] Oncology. 1993 Nov-Dec;50(6):495-9 [8233293.001]
  • [Cites] J Comput Assist Tomogr. 1997 Sep-Oct;21(5):731-2 [9294562.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jun;170(6):1488-90 [9609159.001]
  • [Cites] Dis Colon Rectum. 1998 Aug;41(8):1056-8 [9715165.001]
  • [Cites] Clin Imaging. 2005 Jul-Aug;29(4):251-4 [15967315.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1581-7 [15937630.001]
  • [Cites] Yonsei Med J. 2005 Aug 31;46(4):555-61 [16127782.001]
  • [Cites] AJR Am J Roentgenol. 2006 Aug;187(2):517-21 [16861558.001]
  • [Cites] Int J Colorectal Dis. 2007 Apr;22(4):381-5 [16909248.001]
  • [Cites] Br J Surg. 2008 Feb;95(2):214-21 [17933000.001]
  • [Cites] Abdom Imaging. 2008 Jul-Aug;33(4):498-500 [17680300.001]
  • [Cites] Eur Radiol. 2008 Nov;18(11):2586-93 [18566821.001]
  • [Cites] Can J Surg. 2008 Dec;51(6):E115-6 [19057717.001]
  • [Cites] Am Surg. 2009 Mar;75(3):240-8 [19350861.001]
  • [Cites] Am J Gastroenterol. 2000 May;95(5):1344-7 [10811351.001]
  • [Cites] Radiographics. 2001 May-Jun;21(3):575-84 [11353107.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):705-14 [12023574.001]
  • [Cites] Tech Coloproctol. 2002 Apr;6(1):43-9 [12077641.001]
  • [Cites] Hum Pathol. 2002 May;33(5):456-8 [12094369.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):655-64 [12424067.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S39-51 [12528772.001]
  • [Cites] Surg Oncol. 2003 Jul;12(1):21-6 [12689667.001]
  • [Cites] Tech Coloproctol. 2003 Apr;7(1):55-7 [12750956.001]
  • [Cites] J Am Coll Surg. 2003 Jun;196(6):880-6 [12788424.001]
  • [Cites] Eur Radiol. 2003 Aug;13(8):2053-4 [12942309.001]
  • [Cites] Dis Colon Rectum. 1985 Sep;28(9):644-52 [2996861.001]
  • (PMID = 21155003.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3001973
  •  go-up   go-down


51. Bezsilla J, Bende S, Varga L, Botos A, Liptay-Wagner P, Sikorszki L, Sümegi J, Nagy G: [Laparoscopic colon operations for endoscopically unremovable polyps and tumors]. Magy Seb; 2005 Oct;58(5):305-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic colon operations for endoscopically unremovable polyps and tumors].
  • The use of laparoscopy in colorectal surgery is expanding.
  • Minimally invasive surgery of benign lesions is widely accepted and can be performed with good results even during the learning curve.
  • On one occasion a benign polyp was removed through mini laparotomy after colotomy; 13 resections and 2 subtotal colectomies were performed.
  • [MeSH-major] Colectomy / methods. Colonic Neoplasms / surgery. Colonic Polyps / surgery. Laparoscopy

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16496772.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


52. Robles R, Marín C, Fernández JA, Ramírez P, Sánchez-Bueno F, Morales D, Luján JA, Abellán B, Ramírez M, Cascales P, Pérez D, Parrilla P: [Toward zero mortality in liver resection. Presentation of 200 consecutive cases]. Cir Esp; 2005 Jul;78(1):19-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common indication was liver metastases in 123 patients (61.5%), primary malignant liver tumors in 27 patients (13.5%), bile duct tumors in 27 patients (13.5%) and benign disease in 23 patients (11.5%).
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Carcinoma. Liver Neoplasms
  • [MeSH-minor] Colorectal Neoplasms / mortality. Colorectal Neoplasms / secondary. Colorectal Neoplasms / surgery. Female. Humans. Male. Middle Aged. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cir Esp. 2005 Dec;78(6):392 [16420871.001]
  • [CommentIn] Cir Esp. 2005 Jul;78(1):1-2 [16420783.001]
  • (PMID = 16420786.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Spain
  •  go-up   go-down


53. Somorácz A, Tátrai P, Horváth G, Kiss A, Kupcsulik P, Kovalszky I, Schaff Z: Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas. Hum Pathol; 2010 Sep;41(9):1310-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, we proved the utility of agrin immumohistochemistry in discriminating between HCCs and benign parenchymal lesions.
  • Here, we have examined the expression of agrin in metastatic liver carcinomas in comparison with primary liver tumors.
  • Immunohistochemistry for agrin was performed on 25 HCC, 16 intrahepatic CCC, 20 colorectal cancer metastasis (CRCm), and 18 pancreatic ductal carcinoma metastasis (PDCm) samples and evaluated with both quantitative and qualitative methods.
  • Regardless of tumor grade, agrin immunostaining was strong in the microvessels of HCCs.
  • As opposed to HCC, agrin immunostaining was faint or nearly absent from the CD34-positive microvessels of CCC, CRCm, and PDCm; rather, it was detected in the basement membranes surrounding tumor cell pseudoglandules.
  • [MeSH-major] Adenoma, Liver Cell / pathology. Agrin / metabolism. Carcinoma, Hepatocellular / pathology. Colorectal Neoplasms / secondary. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / metabolism. Bile Duct Neoplasms / genetics. Bile Duct Neoplasms / metabolism. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / metabolism. Bile Ducts, Intrahepatic / pathology. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / secondary. Cholangiocarcinoma / genetics. Cholangiocarcinoma / metabolism. Cholangiocarcinoma / pathology. DNA, Neoplasm / analysis. Diagnosis, Differential. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Female. Gene Expression Regulation, Neoplastic. Hepatectomy. Humans. Male. Microvessels / metabolism. Microvessels / pathology. Middle Aged. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. RNA, Messenger / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20471664.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Agrin; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Messenger
  •  go-up   go-down


54. Davies RJ, Miller R, Coleman N: Screening for colorectal cancer using stool. Discov Med; 2005 Apr;5(26):175-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for colorectal cancer using stool.
  • Extract: Colorectal cancer (CRC, cancer of the large bowel) is the third commonest malignancy worldwide.
  • Most CRCs are thought to arise from benign tumors, known as adenomas, over an interval of at least 5-10 years.
  • Survival is closely related to the stage at which the cancer is discovered (i.e., how advanced a tumor is), with early CRC having an excellent outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20704906.001).
  • [ISSN] 1944-7930
  • [Journal-full-title] Discovery medicine
  • [ISO-abbreviation] Discov Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Achiam MP, Andersen LP, Klein M, Løgager V, Chabanova E, Thomsen HS, Rosenberg J: Differentiation between benign and malignant colon tumors using fast dynamic gadolinium-enhanced MR colonography; a feasibility study. Eur J Radiol; 2010 Jun;74(3):e45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between benign and malignant colon tumors using fast dynamic gadolinium-enhanced MR colonography; a feasibility study.
  • BACKGROUND: Colorectal cancer will present itself as a bowel obstruction in 16-23% of all cases.
  • However, not all obstructing tumors are malignant and the differentiation between a benign and a malignant tumor can be difficult.
  • The purpose of our study was to determine whether fast dynamic gadolinium-enhanced MR imaging combined with MR colonography could be used to differentiate a benign from a malignant obstructing colon tumor.
  • METHODS: Patients with benign colon tumor stenosis, based on diverticulitis, were asked to participate in the study.
  • The same number of patients with verified colorectal cancer was included.
  • Two blinded observers analyzed the tumors on MR by placing a region of interest in the tumor and a series of parameters were evaluated, e.g. wash-in, wash-out and time-to-peak.
  • The wash-in and wash-out rates were significantly different between the benign and malignant tumors, and a clear distinction between benign and malignant disease was therefore possible by looking only at the MR data.
  • CONCLUSION: The results showed the feasibility of using fast dynamic gadolinium-enhanced MR imaging to differentiate between benign and malignant colonic tumors.
  • With a high intra-class correlation and significant differences found on independent segments of the tumor, the method appears to be reproducible.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Diverticulitis / diagnosis. Diverticulitis / etiology. Image Enhancement / methods. Magnetic Resonance Imaging / methods. Meglumine. Organometallic Compounds
  • [MeSH-minor] Adult. Aged. Contrast Media. Diagnosis, Differential. Feasibility Studies. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Single-Blind Method

  • MedlinePlus Health Information. consumer health - Diverticulosis and Diverticulitis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19419830.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00114829
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 0 / gadoterate meglumine; 6HG8UB2MUY / Meglumine
  •  go-up   go-down


56. Halsey MA, Calder KB, Mathew R, Schlauder S, Morgan MB: Expression of alpha-methylacyl-CoA racemase (P504S) in sebaceous neoplasms. J Cutan Pathol; 2010 Apr;37(4):446-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of alpha-methylacyl-CoA racemase (P504S) in sebaceous neoplasms.
  • AMACR has been established as a valuable diagnostic marker for prostate cancer and has recently been shown to be useful in the diagnosis of colorectal carcinoma.
  • Despite the importance of lipid metabolism in sebum production by sebaceous glands of the skin, there are no studies evaluating the expression of AMACR in sebaceous neoplasms.
  • Among sebaceous neoplasms, SH showed the highest expression (4+), SA and BCC with sebaceous differentiation showed varied expression (2+ and 1+, respectively), and extraocular SC showed no expression of AMACR.
  • CONCLUSIONS: The expression of AMACR is increased in benign sebaceous glands and SH; with decreasing AMACR expression in tumors with less sebaceous differentiation (i.e.
  • SA and SC). These findings provide insight into the potential pathogenesis of sebaceous neoplasms while assisting in the microscopic distinction of SA from SC.
  • [MeSH-major] Adenoma / enzymology. Carcinoma / enzymology. Racemases and Epimerases / metabolism. Sebaceous Gland Neoplasms / enzymology. Sebaceous Glands / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19638170.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


57. Vodicka J, Spidlen V, Klecka J, Simánek V, Safránek J: [Use of the KLS Martin Nd:YAG laser MY 40 13 in lung parenchyma surgery]. Rozhl Chir; 2009 May;88(5):248-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Nd:YAG laser MY 40 1.3 has been developed to be employed in lung tumor resections.
  • AIM: Analysis of our initial experience with the use of the instrument in surgical management of primary and secondary lung tumors.
  • In 12 subjects, lung metastases of malignant tumors were detected, 3 subjects suffered from primary lung carcinoma and two from benign lung lesions.
  • 7 operated subjects had multiple secondary lung tumors in various lobes of a single lung or both lungs, in 5 subjects, the secondary tumors were solitary.
  • Most commonly--in 7 cases, the subjects suffered from colorectal carcinoma metastases.
  • The two benign lesions were managed in a similar way.
  • CONCLUSION: Nd:YAG laser MY 40 1.3 facilitates radical removals of secondary pulmonary neoplasms, in particular of the multiple and deeply located ones, with no need for extensive lung parenchyma resections and with minimum intraoperative morbidity and mortality rates.
  • Furthermore, it can be successfully used in a numer of other surgical procedures, such as management of pleural adhesions, lung biopsies, resections of emphysematous bullae, resections of benign lung tumors, dissections of inerlobal fissures, etc., where the method can fully replace staplers.
  • [MeSH-major] Laser Therapy / instrumentation. Lasers, Solid-State / therapeutic use. Lung Neoplasms / surgery. Pneumonectomy / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19642342.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


58. Céspedes MV, Sancho FJ, Guerrero S, Parreño M, Casanova I, Pavón MA, Marcuello E, Trias M, Cascante M, Capellà G, Mangues R: K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12. Carcinogenesis; 2006 Nov;27(11):2190-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Different mutant amino acids in the Ras proteins lead to distinct transforming capacities and different aggressiveness in human tumors.
  • K-Ras Asp12 (K12D) is more prevalent in benign than in malignant human colorectal tumors, whereas K-Ras Val12 (K12V) associates with more advanced and metastatic carcinomas, higher recurrence and decreased survival.
  • We studied tumor histology and growth, apoptotic and mitotic rates, activation of signal transduction pathways downstream of Ras and regulation of the cell cycle and apoptotic proteins in tumors derived from the implanted transformants.
  • We found that the K12V oncogene induces a more aggressive tumorigenic phenotype than the K12D oncogene, whereas K12C does not induce tumors in this model.
  • Thus, K12V mutant tumors proliferate about seven times faster, and have higher cellularity and mitotic rates than the K12D mutant tumors.
  • A molecular analysis of the induced tumors shows that the K12V mutant protein interacts with Raf-1 and transduces signals mainly through the Erk pathway.
  • Unexpectedly, in tumors induced by the K12D oncogene, the K-Ras mutant protein does not interact with Raf-1 nor activates the Erk canonical pathway.
  • Finally, the higher growth rate of the K12V tumors associates with enhanced Rb phosphorylation, and PCNA and cyclin B upregulation, consistent with faster G1/S and G2/M transitions, without alteration of apoptotic regulation.
  • [MeSH-minor] Animals. Apoptosis. Male. Mice. Mice, Nude. NIH 3T3 Cells. Neoplasm Metastasis. Protein Binding. Signal Transduction


59. Schäfer H, Baldus SE, Hölscher AH: Giant adenomas of the rectum: complete resection by transanal endoscopic microsurgery (TEM). Int J Colorectal Dis; 2006 Sep;21(6):533-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Large sessile adenomas of the rectum, with a diameter greater than 5 cm, have a high risk to undergo malignant transformation.
  • Transanal endoscopic microsurgery (TEM) offers an alternative operation method to low-anterior rectum resection in this potentially benign tumor situation.
  • A total of 33 patients met the criteria and were analyzed for postoperative complications, histology, and incidence of occult adenocarcinoma; residual tumor status; and tumor recurrence.
  • The residual adenoma status was 18% (n=6), especially in patients with tumors sizes more than 30 cm2.
  • In case of adenoma recurrence (n=4, 12%), a conventional transanal excision (Parks) was applicable, as these tumors were mostly located within the suture-line region of the lower rectum.
  • In case of advanced tumors (1xpT2, 1xpT3), anterior rectum resection was carried out, whereas for the early tumors (2xpT1 low risk, 1x1 pTis), no further therapy was added.
  • CONCLUSION: TEM is an alternative method for the resection of large benign rectal tumors located in the mid- and upper third of the rectum.
  • [MeSH-major] Adenoma / surgery. Colonoscopy / methods. Microsurgery. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1987 Jan;153(1):41-7 [3799891.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):340-8 [12626909.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1021-6 [15789125.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):255-9 [15273549.001]
  • [Cites] Dis Colon Rectum. 1995 Mar;38(3):233-8 [7882783.001]
  • [Cites] Surg Endosc. 1995 Oct;9(10):1106-12 [8553213.001]
  • [Cites] Int J Colorectal Dis. 2003 Mar;18(2):131-5 [12548415.001]
  • [Cites] Proc R Soc Med. 1974 Jun;67(6 Pt 1):451-7 [4853754.001]
  • [Cites] Dis Colon Rectum. 2004 Jan;47(1):86-9 [14702647.001]
  • [Cites] Endoscopy. 2003 Aug;35(8):S41-4 [12929053.001]
  • [Cites] Curr Top Pathol. 1990;81:277-93 [2407443.001]
  • [Cites] Am Surg. 1998 Dec;64(12):1170-3 [9843338.001]
  • [Cites] Br J Surg. 1973 Sep;60(9):688-95 [4582241.001]
  • [Cites] Am J Surg. 1997 May;173(5):383-5 [9168071.001]
  • [Cites] Ann Surg. 1988 Jan;207(1):65-71 [3337563.001]
  • [Cites] Am J Surg. 1976 Feb;131(2):185-91 [175719.001]
  • [Cites] Am J Surg. 1975 Dec;130(6):729-32 [1200290.001]
  • [Cites] Chirurg. 2005 Apr;76(4):379-84 [15502890.001]
  • [Cites] Gastrointest Endosc. 1996 Mar;43(3):183-8 [8857131.001]
  • [Cites] Gastrointest Endosc. 1984 Feb;30(1):18-20 [6706083.001]
  • [Cites] Surg Clin North Am. 1997 Feb;77(1):229-39 [9092112.001]
  • [Cites] Am J Surg. 1992 Jan;163(1):63-9; discussion 69-70 [1733375.001]
  • (PMID = 16133003.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


60. Maksimović RM, Dunjić MS, Lilić GB, Milenković RM, Masulović DM, Milićević M: [Diagnostic value of diffusion weighted imaging in assessment of malignant focal liver lesions]. Acta Chir Iugosl; 2009;56(4):121-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: The study included 63 patients with focal hepatic lesions: fourteen patients (22.2%) with hepatocellular carcinoma (HCC), 16 patients (25.4%) with hepatic metastatic colorectal tumors, 17 patients (26.9%) with cavernous haemangioma and 16 patients (25.4%) with hepatic cysts.
  • Furthermore, there was statistically significant difference between benign lesions (haemangiom and cysts, 2.36 +/- 0.43 x 10(-3) s/mm2), and malignant diseases (HCC and secondary tumors, 1.52 +/- 0.58 x 10(-3) s/mm2), t = 5,6, p < 0.01.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging. Liver Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Hepatocellular / diagnosis. Female. Hemangioma, Cavernous / diagnosis. Humans. Liver Diseases / diagnosis. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20420007.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


61. Jiang W, Fujii H, Matsumoto T, Ohtsuji N, Tsurumaru M, Hino O: Birt-Hogg-Dubé (BHD) gene mutations in human gastric cancer with high frequency microsatellite instability. Cancer Lett; 2007 Apr 8;248(1):103-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Birt-Hogg-Dubé (BHD) syndrome is a rare inherited genodermatosis characterized by benign hamartomatous skin lesions and an increased risk of pneumothorax and renal tumors.
  • This mutational hot spot is also reported to be a target of mutation in microsatellite instability (MSI) sporadic colorectal tumors.
  • [MeSH-major] Microsatellite Instability. Mutation. Proteins / genetics. Proto-Oncogene Proteins / genetics. Stomach Neoplasms / pathology. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. DNA Mutational Analysis. Exons / genetics. Female. Gene Frequency. Humans. Male. Middle Aged. Neoplasm Staging. Poly C / genetics. Protein-Serine-Threonine Kinases. Receptors, Transforming Growth Factor beta / genetics. bcl-2-Associated X Protein / genetics

  • Genetic Alliance. consumer health - Birt-Hogg-Dube Syndrome.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16870330.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / FLCN protein, human; 0 / Proteins; 0 / Proto-Oncogene Proteins; 0 / Receptors, Transforming Growth Factor beta; 0 / Tumor Suppressor Proteins; 0 / bcl-2-Associated X Protein; 30811-80-4 / Poly C; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


62. Königsrainer I, Steurer W, Witte M, Königsrainer A: Liver resection without hilus preparation and with selective intrahepatic hilus stapling for benign tumors and liver metastasis. Langenbecks Arch Surg; 2007 Jul;392(4):485-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection without hilus preparation and with selective intrahepatic hilus stapling for benign tumors and liver metastasis.
  • Extrahepatic isolation of portal vein, hepatic artery and hepatic duct, as well as lymphadenectomy of the liver hilum are generally accepted steps of liver resection, even for metastatic and benign indications.
  • MATERIALS AND METHODS: Thirty-eight consecutive patients with resection for metastases and benign liver tumors were selected.
  • To date, no tumor recurrence was found in the hilum during the follow-up period.
  • Hilar dissection can, thus, be avoided in liver metastasis and benign liver tumors.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery. Surgical Stapling
  • [MeSH-minor] Aged. Colorectal Neoplasms / pathology. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1999 Oct;42(10):1285-90; discussion 1290-1 [10528765.001]
  • [Cites] J Surg Oncol. 2005 Apr 1;90(1):43-5 [15786414.001]
  • [Cites] Ann Surg. 2006 Jan;243(1):137-8; author reply 138 [16371749.001]
  • [Cites] Ann Surg. 2005 Apr;241(4):582-90 [15798459.001]
  • [Cites] Br J Surg. 2006 Jun;93(6):685-9 [16703653.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(3):286-91 [9880776.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):202-9 [14745328.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):260-4 [16858189.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):111-9 [12832973.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):397-406; discussion 406-7 [12368667.001]
  • [Cites] World J Surg. 1995 Sep-Oct;19(5):764-7 [7571678.001]
  • [Cites] Ann Surg. 2001 Jan;233(1):45-50 [11141224.001]
  • [Cites] Ann Surg. 1996 Aug;224(2):155-61 [8757378.001]
  • [Cites] Ann Surg. 1997 Dec;226(6):704-11; discussion 711-3 [9409569.001]
  • [Cites] World J Gastroenterol. 2006 Feb 14;12(6):935-9 [16521223.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):942-5 [8813780.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):121-4 [8653335.001]
  • [Cites] Ann Surg. 1999 Feb;229(2):210-5 [10024102.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):814-22, discussion 822-3 [16327491.001]
  • (PMID = 17530278.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


63. Oh SJ, Lee SJ, Lee HY, Paik YH, Lee DK, Lee KS, Chung JB, Yu JS, Yoon DS: [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas]. Korean J Gastroenterol; 2009 Sep;54(3):162-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas].
  • BACKGROUND/AIMS: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas has a favorable prognosis, but seems to be associated with a high incidence of extrapancreatic tumors.
  • The purpose of this study was to evaluate the incidence and clinicopathological features of extrapancreatic tumors associated with IPMN.
  • These patients were examined for the development of extrapancreatic tumors.
  • RESULTS: Of 37 patients with IPMN, 14 (38%) had 18 extrapancreatic tumors, and 10 (27%) had 13 extrapancreatic malignancies.
  • Five, six, and two extrapancreatic malignancies had been diagnosed before, during, and after the diagnosis of IPMN.
  • Gastric adenocarcinoma (3 patients, 23%) and colorectal carcinoma (3 patients, 23%) were the most common neoplasms.
  • Other extrapancreatic tumors included lung cancer (n=2), prostatic cancer (n=1), renal cell carcinoma (n=1), cholangiocellular carcinoma (n=1), urinary bladder cancer (n=1), and gallbladder cancer (n=1), respectively.
  • As benign tumor, there were two gallbladder adenoma, one gastric adenoma, one colonic adenoma and one benign ovarian cystic neoplasm, respectively.
  • CONCLUSIONS: IPMN is associated with high incidence of extrapancreatic tumors, particularly gastric and colorectal neoplasms.
  • Upper gastrointestinal endoscopy and colonoscopy should be done, and systemic surveillance for the possible occurrence of other tumors may allow early detection of extrapancreatic tumor in patients with IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Neoplasms, Multiple Primary / epidemiology. Neoplasms, Second Primary / epidemiology. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Korean J Gastroenterol. 2009 Sep;54(3):196-8 [19844158.001]
  • (PMID = 19844152.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


64. Gao Y, Zhang B: [Expression of TEIF protein in colorectal tumors and its correlation with centrosome abnormality]. Ai Zheng; 2009 Dec;28(12):1277-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of TEIF protein in colorectal tumors and its correlation with centrosome abnormality].
  • BACKGROUND AND OBJECTIVE: Telomerase transcriptional elements-interacting factor (TEIF) gene found recently by our research group is a transcription factor of a kind of human telomerase reverse transcriptase (hTERT) gene, and expresses in many kinds of tumor tissues.
  • This study was to evaluate the expression of TEIF protein in human colorectal tumors and to explore its correlation with centrosome abnormality.
  • METHODS: The expression of TEIF in 10 specimens of normal intestinal mucosa tissue, 30 specimens of colorectal cancer, and 54 specimens of colorectal adenoma was detected by immunohistochemistry.
  • RESULTS: Immunohistochemistry results showed that the differences of TEIF protein expression between the normal group and each tumor groups were statistically significant (P<0.01), and the difference of TEIF protein expression between the malignant tumor group and the benign group was not significant (P>0.05).
  • Immunofluorescence results showed that centrosome amplification-positive rate was significantly higher in the colorectal cancer group than in the normal group or the adenoma group (both P<0.01); the difference of the centrosome amplification positive rate between Grade I adenoma and Grade III adenoma was statistically significant (P<0.05), and the differences of the centrosome amplification positive rate between Grade II adenoma and Grade I or III adenoma were statistically significant (P>0.05).
  • CONCLUSIONS: TEIF protein and centrosome amplification is commonly found in colorectal tumors.
  • The expression level of TEIF is related to tumor histological grade and malignant degree.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Centrosome / pathology. Colorectal Neoplasms / metabolism. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958622.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Transcription Factors; 0 / Tubulin; EC 2.7.1.- / SCYL1 protein, human
  •  go-up   go-down


65. Boni L, Dionigi G, Cassinotti E, Di Giuseppe M, Diurni M, Rausei S, Cantore F, Dionigi R: Single incision laparoscopic right colectomy. Surg Endosc; 2010 Dec;24(12):3233-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laparoscopic surgery has been fully validated as alternative, minimally invasive treatment for different benign and malignant conditions.
  • METHODS: After signed, informed consent was obtained, patients with malignant tumors or large polyps of the right colon underwent single-incision colonic resection through a 3-cm incision using two different single-port devices and articulated or coaxial curved instruments.
  • The mean postoperative stay was 5 ± 1.2 days (range, 4-14), and mean lymph node retrieval and tumor-free margins was 24 ± 7 (range, 29-15) and 8 ± 3 (range, 6-12) cm, respectively.
  • [MeSH-major] Colectomy / methods. Colorectal Neoplasms / surgery. Laparoscopy / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2007 Mar;204(3):439-46 [17324779.001]
  • [Cites] Int J Colorectal Dis. 2008 Oct;23(10):1013-6 [18607608.001]
  • [Cites] Colorectal Dis. 2011 Apr;13(4):393-8 [20002691.001]
  • [Cites] Cancer Treat Rev. 2008 Oct;34(6):498-504 [18468803.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Gastrointest Endosc. 2008 Oct;68(4):760-6 [18926184.001]
  • [Cites] Colorectal Dis. 2008 Oct;10(8):823-6 [18684153.001]
  • [Cites] Surg Endosc. 2009 Jul;23(7):1419-27 [19347400.001]
  • [Cites] Surg Endosc. 2010 Apr;24(4):888-90 [19760335.001]
  • [Cites] Dis Colon Rectum. 2009 Apr;52(4):725 [19404081.001]
  • [Cites] Surg Endosc. 2007 Sep;21(9):1503-7 [17641928.001]
  • [Cites] Surg Technol Int. 2009 Apr;18:19-25 [19579186.001]
  • [Cites] Gastrointest Endosc. 2007 Jan;65(1):111-7 [17185089.001]
  • [Cites] Ann Surg. 2009 Jun;249(6):908-12 [19474690.001]
  • [Cites] Dis Colon Rectum. 2009 May;52(5):1021-4 [19502875.001]
  • [Cites] Surgeon. 2008 Dec;6(6):357-60 [19110824.001]
  • [Cites] Arch Surg. 2009 Aug;144(8):734-8 [19687377.001]
  • (PMID = 20464415.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


66. Jin Z, Yin L, Xue L, Lin M, Zheng Q: Anorectal functional results after transanal endoscopic microsurgery in benign and early malignant tumors. World J Surg; 2010 May;34(5):1128-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anorectal functional results after transanal endoscopic microsurgery in benign and early malignant tumors.
  • Thus TEM is safe, in terms of anorectal function, for the cure of benign and early malignant tumors of the rectum.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma, Villous / surgery. Anal Canal / physiopathology. Anus Neoplasms / surgery. Rectal Neoplasms / surgery. Rectum / physiopathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 1965 Feb;6:64-8 [14259425.001]
  • [Cites] Chirurg. 1984 Oct;55(10):677-80 [6510078.001]
  • [Cites] Br J Surg. 1989 Aug;76(8):783-6 [2765827.001]
  • [Cites] Lancet. 1986 Apr 19;1(8486):886-8 [2870357.001]
  • [Cites] Gut. 1999 Jan;44(1):77-80 [9862829.001]
  • [Cites] Colorectal Dis. 2000 Jul;2(4):193-202 [23578077.001]
  • [Cites] Endoscopy. 1987 Nov;19 Suppl 1:38-42 [3428240.001]
  • [Cites] Dis Colon Rectum. 2002 May;45(5):601-4 [12004207.001]
  • [Cites] Rev Esp Enferm Dig. 2000 Aug;92(8):526-35 [11084820.001]
  • [Cites] Br J Surg. 1980 Sep;67(9):655-7 [7427068.001]
  • [Cites] Br J Surg. 1997 Mar;84(3):348-51 [9117305.001]
  • [Cites] Surg Endosc. 1988;2(2):71-5 [3413659.001]
  • [Cites] Colorectal Dis. 2002 Jan;4(1):51-55 [12780656.001]
  • [Cites] Endoscopy. 1985 Jan;17(1):31-5 [3971938.001]
  • [Cites] Cir Esp. 2007 Nov;82(5):285-9 [18021627.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1283-7 [12739119.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):211-3 [8689165.001]
  • [Cites] Colorectal Dis. 2005 Mar;7(2):133-7 [15720349.001]
  • [Cites] Br J Surg. 1977 Aug;64(8):596-9 [890286.001]
  • [Cites] Gut. 1963 Jun;4(2):179-82 [18668760.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1376-80 [14571741.001]
  • [Cites] Int J Colorectal Dis. 2001 Nov;16(6):370-6 [11760898.001]
  • [Cites] Dis Colon Rectum. 1992 Sep;35(9):874-8 [1511649.001]
  • [Cites] Br J Surg. 1992 Dec;79(12):1381-2 [1486447.001]
  • [Cites] Rev Esp Enferm Dig. 2006 Apr;98(4):234-40 [16792452.001]
  • [Cites] Ann Surg. 1986 Aug;204(2):133-5 [3741004.001]
  • [Cites] Surg Endosc. 1988;2(4):245-50 [3071872.001]
  • [Cites] Br J Surg. 1988 Jan;75(1):44-7 [3337950.001]
  • [Cites] Br J Surg. 1980 Mar;67(3):203-8 [7362963.001]
  • [Cites] Gut. 1975 Jun;16(6):482-9 [1150119.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]
  • [Cites] Dis Colon Rectum. 1996 Oct;39(10):1116-21 [8831526.001]
  • [Cites] Int J Colorectal Dis. 1989;4(2):118-22 [2746132.001]
  • [Cites] Scand J Gastroenterol Suppl. 1974;25:1-64 [4522807.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1145-51 [10496554.001]
  • [Cites] Ann Surg Oncol. 1999 Jul-Aug;6(5):433-41 [10458680.001]
  • [Cites] Br J Surg. 1990 Mar;77(3):280-2 [1691033.001]
  • [Cites] Dis Colon Rectum. 2000 Feb;43(2):169-73 [10696889.001]
  • [Cites] Br J Surg. 1996 Oct;83(10):1335-44 [8944447.001]
  • (PMID = 20225126.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Kume K, Murata I, Yoshikawa I, Yamasaki M, Kanda K, Otsuki M: Endoscopic piecemeal mucosal resection of large colorectal tumors. Hepatogastroenterology; 2005 Mar-Apr;52(62):429-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic piecemeal mucosal resection of large colorectal tumors.
  • BACKGROUND/AIMS: Since endoscopic en bloc resection of large and sessile tumors is technically difficult, endoscopic en bloc piecemeal mucosal resection (EPMR) is usually chosen for resection of such tumors.
  • Tumors resected by EPMR are, however, difficult to evaluate histologically.
  • METHODOLOGY: We removed 30 large colorectal tumors in 30 patients by EPMR between 1992-2000.
  • Patients in whom no residual tumor was found by both endoscopic and histologic examination were considered to be "cured".
  • RESULTS: Histological examination of the resected tumor tissues revealed malignancy in 43.3% (13/30).
  • Three patients had invasive malignant tumors and underwent surgery.
  • Following complete endoscopic resection, recurrences were observed in 2 patients with benign tumors, which were resected by additional endoscopic resection.
  • All patients including the two with non-invasive malignant tumors remain free from recurrence during a mean follow-up period of 45.2 months (range, 3-104 months).
  • CONCLUSIONS: EPMR of benign or non-invasive large malignant tumors is a safe and effective procedure.
  • Complete excision of large, sessile and non-invasive tumors is possible, although complete removal by EPMR cannot be verified histologically.
  • [MeSH-major] Adenoma / surgery. Carcinoma / surgery. Colorectal Neoplasms / surgery. Endoscopy, Digestive System / methods. Intestinal Mucosa / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colonoscopy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816450.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


68. Saad RS, Silverman JF, Khalifa MA, Rowsell C: CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma. Appl Immunohistochem Mol Morphol; 2009 May;17(3):196-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CK20/CK7 immunoprofile of colorectal adenocarcinoma has been described in studies, which have mostly lumped colonic and rectal tumors together.
  • CDX2 showed moderate-strong positivity in all cases and was not related to tumor differentiation.
  • Benign rectal mucosa was available in 37 cases and showed the following results: CK7-/CK20+ in 25/37 (67%), CK7+/CK20+ in 8/37 (22%) and CK7-/CK20- in 4/37 (11%) cases.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Appl Immunohistochem Mol Morphol. 2009 Oct;17(5):464
  • (PMID = 19098678.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


69. Abbasova SG, Vysotskii MM, Ovchinnikova LK, Obusheva MN, Digaeva MA, Britvin TA, Bahoeva KA, Karabekova ZK, Kazantzeva IA, Mamedov UR, Manuchin IB, Davidov MI: Cancer and soluble FAS. Bull Exp Biol Med; 2009 Oct;148(4):638-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A test system developed by the authors was used to measure serum concentrations of soluble Fas in patients with malignant and benign tumors of different location and morphology.
  • It is proven that the concentrations and incidence of detection of soluble Fas in the sera of patients with tumors are significantly higher than in normal subjects.
  • No appreciable differences in the concentrations of soluble Fas were detected in malignant and benign tumors of the mammary gland, bones, ovaries, and adrenals.
  • In thyroid cancer, soluble Fas levels were higher than in benign and hyperplastic processes in this organ.
  • High level of soluble Fas is associated with late stages of the disease (ovarian cancer, cancer of the corpus uteri, adrenocortical and colorectal cancer) and with poor differentiation of the tumor (ovarian cancer and cancer of the corpus uteri), with local metastases (colorectal and adrenocortical cancer), and with tumor invasion into the myometrial tissue, intestinal wall, and adjacent tissues (cancer of the corpus uteri and colorectal cancer).
  • A significantly high level of soluble Fas was detected in colorectal and adrenocortical cancer in the presence of at least 2 local metastases.
  • Soluble Fas levels depended on tumor histogenesis in malignant and benign ovarian tumors.
  • High concentration of soluble Fas was detected in large tumors in patients with ovarian cancer, cancer of the corpus uteri, colorectal cancer, thyroid cancer and adenoma, and in adrenocortical cancer.
  • Initially high levels of soluble Fas are characteristic of patients whose tumors are little sensitive to nonadjuvant radiotherapy.
  • [MeSH-major] Antigens, CD95 / blood. Neoplasms / blood

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20396760.001).
  • [ISSN] 1573-8221
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95
  •  go-up   go-down


70. Brosseuk D, Oosthuizen J, Pinchbeck M: Initial experience with a general population colorectal cancer screening clinic. Am J Surg; 2006 May;191(5):669-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial experience with a general population colorectal cancer screening clinic.
  • BACKGROUND: Recognition of adenoma to carcinoma progression has established colorectal cancer as a preventable malignancy.
  • Colorectal cancer is, therefore, an ideal malignancy for preventative screening given the presence of a benign precursor.
  • METHODS: A retrospective chart review of all patients referred to a new low-risk colorectal cancer endoscopic screening clinic from October 1, 2004 to September 30, 2005 was performed.
  • Those patients found to have adenomas or carcinomas were analyzed further regarding location of neoplasm and pathologic findings.
  • RESULTS: A total of 379 low-risk patients attended the colorectal cancer screening clinics.
  • Of the 67 patients with neoplasms, 50 were left of the splenic flexure, 11 were right of the splenic flexure, and 5 patients had lesions both proximal and distal to the flexure.
  • Thirty-two of the 67 patients had complete colonoscopy at the initial procedure and, thus far, 21 patients have had completion colonoscopies, of which 9 patients had further neoplasms identified beyond the splenic flexure.
  • All 3 patients with carcinoma had early tumors resected with curative intent, with negative margins and negative nodes.
  • CONCLUSIONS: Our initial experience with a low-risk general population colorectal cancer endoscopic screening clinic yielded 18% of patients with neoplasms, and 1% had curable cancers resected.
  • [MeSH-major] Cancer Care Facilities. Colonoscopy. Colorectal Neoplasms / diagnosis. Mass Screening / methods
  • [MeSH-minor] Aged. Aged, 80 and over. British Columbia / epidemiology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies. Risk Factors. Video Recording


71. Nordgård O, Oltedal S, Kørner H, Aasprong OG, Tjensvoll K, Gilje B, Heikkilä R: The potential of cytokeratin 20 and mucin 2 mRNA as metastasis markers in regional lymph nodes of colon cancer patients investigated by quantitative RT-PCR. Int J Colorectal Dis; 2009 Mar;24(3):261-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Both assays were able to detect dilutions of tumor cells down to one tumor cell in 10(6) normal lymphocytes.
  • CK20 and MUC2 mRNA were quantitated in 52 normal lymph nodes from 12 patients undergoing surgery for benign bowel diseases and in 144 primary colon tumors.
  • The median tumor level of both markers were more than 10(4)-fold higher than the highest level in normal lymph nodes, indicating that the markers had a potential for metastasis detection in a clinical context.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Keratin-20 / genetics. Lymph Nodes / pathology. Mucin-2 / genetics. Reverse Transcriptase Polymerase Chain Reaction
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Lymphocytes / metabolism. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Biochem. 2006 Sep 15;356(2):182-93 [16899212.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1070-80 [17206482.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Int J Colorectal Dis. 2004 Mar;19(2):87-94 [13680284.001]
  • [Cites] World J Surg. 2007 Jun;31(6):1304-12 [17460811.001]
  • [Cites] Cancer Detect Prev. 2000;24(1):72-9 [10757125.001]
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):412-7 [14648708.001]
  • [Cites] Ann Surg Oncol. 2006 Nov;13(11):1386-92 [17009147.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1049-55 [11844829.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):101-10 [15185350.001]
  • [Cites] Nat Biotechnol. 2001 Nov;19(11):1011-2 [11689839.001]
  • [Cites] Clin Chem. 2006 Mar;52(3):520-3 [16510433.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):617-28 [14520701.001]
  • [Cites] Br J Cancer. 2006 Jul 17;95(2):218-25 [16755296.001]
  • [Cites] J Mol Diagn. 2007 Nov;9(5):563-71 [17916603.001]
  • (PMID = 19119477.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Mucin-2; 0 / RNA, Messenger
  •  go-up   go-down


72. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J: SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem; 2009 Jul 3;284(27):18210-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.
  • Determination of SirT1 function in tumor cells is important for its targeting in cancer therapy.
  • We found that SirT1 knockdown by short hairpin RNA accelerates tumor xenograft formation by HCT116 cells, whereas SirT1 overexpression inhibits tumor formation.
  • Immunohistochemical staining revealed high level SirT1 in normal colon mucosa and benign adenomas.
  • SirT1 overexpression was observed in approximately 25% of stage I/II/III colorectal adenocarcinomas but rarely found in advanced stage IV tumors.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 17;403(6771):795-800 [10693811.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2126-8 [11000115.001]
  • [Cites] Nature. 2001 Mar 8;410(6825):227-30 [11242085.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):191-6 [12939617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10794-9 [12960381.001]
  • [Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]
  • [Cites] EMBO J. 2004 Jun 16;23(12):2369-80 [15152190.001]
  • [Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):113-8 [15744310.001]
  • [Cites] Cell Metab. 2005 Jul;2(1):67-76 [16054100.001]
  • [Cites] Cell Metab. 2005 Aug;2(2):105-17 [16098828.001]
  • [Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10457-63 [16288037.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):28-38 [16354677.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):176-85 [16170353.001]
  • [Cites] PLoS Biol. 2006 Feb;4(2):e31 [16366736.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4368-77 [16618762.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1025-31 [16892051.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8122-35 [16923962.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):337-42 [17086191.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1109-22 [17112576.001]
  • [Cites] Mol Cell. 2007 Feb 23;25(4):543-57 [17317627.001]
  • [Cites] Arch Dermatol Res. 2007 May;299(2):103-6 [17180656.001]
  • [Cites] Mol Cell. 2007 Jul 6;27(1):149-62 [17612497.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6612-8 [17638871.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5489-504 [17694089.001]
  • [Cites] Biochem J. 2007 Nov 1;407(3):451-60 [17620057.001]
  • [Cites] Biotechnol J. 2007 Nov;2(11):1360-8 [17806102.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):712-6 [18046409.001]
  • [Cites] Mol Biol Cell. 2008 Mar;19(3):1210-9 [18184747.001]
  • [Cites] PLoS One. 2008;3(4):e2020 [18414679.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):312-23 [18835033.001]
  • (PMID = 19433578.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / R01 CA112215-03; United States / NCI NIH HHS / CA / CA121291; United States / NCI NIH HHS / CA / R01 CA121291; United States / NCI NIH HHS / CA / CA112215-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Small Interfering; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2709385
  •  go-up   go-down


73. Vogelsang H, Siewert JR: Endocrine tumours of the hindgut. Best Pract Res Clin Gastroenterol; 2005 Oct;19(5):739-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroendocrine tumours of the colon and rectum are rare but distinct with regard to clinical symptoms, diagnostic and therapeutic management and prognosis compared to other neuroendocrine tumours of the gut as well as ordinary colorectal cancer.
  • As most rectal neuroendocrine tumours are benign because of submucosal extension only, the size and infiltration depth correlates with lymph-node and distant metastases and therefore with the prognosis.
  • [MeSH-major] Colectomy / methods. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery
  • [MeSH-minor] Anastomosis, Surgical. Biopsy, Needle. Colonoscopy / methods. Female. Humans. Incidence. Male. Neoplasm Staging. Prognosis. Rare Diseases. Risk Assessment. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253898.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 37
  •  go-up   go-down


74. Griniatsos J, Michail O: Appendiceal neuroendocrine tumors: Recent insights and clinical implications. World J Gastrointest Oncol; 2010 Apr 15;2(4):192-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appendiceal neuroendocrine tumors: Recent insights and clinical implications.
  • New insights emerged last decade that enriched our knowledge regarding the biological behavior of appendiceal neuroendocrine tumors (NETs), which range from totally benign tumors less than 1cm to goblet cell carcinomas which behave similarly to colorectal adenocarcinoma.
  • Since the diagnosis is usually established post-appendicectomy, current recommendations focus on the early detection of:.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160597.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999180
  • [Keywords] NOTNLM ; Appendiceal carcinoids / Goblet cell carcinoma / Neuroendocrine tumors / Right hemicolectomy
  •  go-up   go-down


75. Metser U, You J, McSweeney S, Freeman M, Hendler A: Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. AJR Am J Roentgenol; 2010 Mar;194(3):766-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
  • OBJECTIVE: The purpose of this study was to compare FDG PET/CT and contrast-enhanced 64-MDCT of the chest, abdomen, and pelvis in the detection of tumor recurrence in patients with colorectal cancer and an elevated level of carcinoembryonic antigen (CEA).
  • MATERIALS AND METHODS: A retrospective analysis included 50 patients (31 men, 19 women; mean age, 61 years; range, 28-89 years) with 55 clinical events of elevated or increasing CEA level who underwent FDG PET/CT and MDCT for suspected tumor recurrence.
  • Fifty-four of 61 tumor sites suspected as tumor recurrence with any imaging technique were found to be local recurrence or metastatic colorectal cancer at final analysis.
  • The other seven sites were one separate malignant tumor (small lymphocytic lymphoma) and six benign lesions.
  • Diagnosis was based on histopathologic findings (n = 27) or clinical and imaging findings (n = 35) during a median follow-up period of 12 months (range, 6-31 months).
  • One site of tumor recurrence was missed prospectively at both MDCT and PET/CT.
  • In a tumor site-based analysis, the sensitivities of PET/CT and MDCT were 98.1% and 66.7% (p < 0.0001), and the specificities were 75% and 62.5% (p = 0.56).
  • Tumors correctly identified with PET/CT and missed with MDCT were local recurrence in the presacral space (n = 5), metastatic subcentimeter lymph nodes (n = 4), peritoneal deposits (n = 3), and recurrences at the periphery of radiofrequency ablated metastatic lesions of the liver (n = 2) and in the abdominal wall (n = 1), liver (n = 1), and uterine cervix (n = 1).
  • CONCLUSION: FDG PET/CT has higher sensitivity than MDCT in the identification of sites of recurrent and metastatic disease in patients with colorectal cancer and an elevated CEA level.
  • [MeSH-major] Colorectal Neoplasms / radiography. Colorectal Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoembryonic Antigen / blood. Contrast Media. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / radiography. Neoplasm Metastasis / radionuclide imaging. Radiographic Image Interpretation, Computer-Assisted. Radiography, Abdominal. Radiography, Thoracic. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173157.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


76. Uenoyama Y, Seno H, Fukuda A, Sekikawa A, Nanakin A, Sawabu T, Kawada M, Kanda N, Suzuki K, Yada N, Fukui H, Chiba T: Hypoxia induced by benign intestinal epithelial cells is associated with cyclooxygenase-2 expression in stromal cells through AP-1-dependent pathway. Oncogene; 2006 Jun 1;25(23):3277-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia induced by benign intestinal epithelial cells is associated with cyclooxygenase-2 expression in stromal cells through AP-1-dependent pathway.
  • Cyclooxygenase-2 (COX-2) plays important roles in tumor development.
  • Especially in the early-stage colorectal tumors, COX-2 expression is often observed in the tumor stroma.
  • In the present study, we simulated the indirect interaction between epithelial cells and stromal cells in the process of colorectal tumor development using an in vitro co-culture model in which NIH3T3 fibroblasts were co-cultured with 'sparsely' or 'densely' populated intestinal epithelial cells, Intestine-407 as a model of premalignant or benign intestinal epithelial cells, and DLD-1 and Caco-2 as models of malignant epithelial cells.
  • Interestingly, there was pericellular hypoxia in the vicinity of NIH3T3 fibroblasts when co-cultured with 'dense' epithelial cells, and the recovery of the partial pressure of oxygen level resulted in the reduction of enhanced COX-2 expression only in NIH3T3 fibroblasts co-cultured with 'dense' Intestine-407 cells.
  • Thus, pericellular hypoxia of the stromal cells caused by densely populated epithelial cells may be one of the potent COX-2 enhancers before completion of malignant transformation during intestinal tumor development.
  • [MeSH-minor] Animals. Caco-2 Cells. Cell Count. Cell Line, Tumor. Coculture Techniques. Enzyme Induction / physiology. Humans. Mice. NIH 3T3 Cells. Precancerous Conditions / enzymology. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Stromal Cells / enzymology. Stromal Cells / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16407821.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Transcription Factor AP-1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


77. Vereczkey I, Tóth E, Orosz Z: [Diagnostic problems of ovarian mucinous borderline tumors]. Magy Onkol; 2009 Jun;53(2):127-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic problems of ovarian mucinous borderline tumors].
  • About 15-20% of all ovarian epithelial neoplasms are of borderline type (or atypical proliferative or carcinoma of low malignant potential) and about 5-7% are mucinous type, which are the second most common type behind the serous borderline tumors.
  • The borderline tumor is a serious diagnostic and treatment problem both for the pathologists and for clinicians.
  • These tumors appeared to be intermediate in their histologic and prognostic features between the benign cystadenomas and clearly malignant carcinomas.
  • The borderline tumors occur most commonly in childbearing age, and show an indolent course.
  • To diagnose the intraepithelial carcinoma, to detect the microinvasion and the expansive invasion in a mucinous borderline tumor, to differentiate from the metastasis of colorectal tumors may be very problematic in the majority of the cases.
  • Eleven cases diagnosed as mucinous borderline ovarian tumor in our institute from 2000 to 2008 were reviewed.
  • In 5 cases our diagnosis was intraepithelial carcinoma and in 5 cases we found microinvasion.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / analysis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. CA-125 Antigen / analysis. Diagnosis, Differential. Female. GPI-Linked Proteins. Homeodomain Proteins / analysis. Humans. Keratin-20 / analysis. Keratin-7 / analysis. Membrane Glycoproteins / analysis. Middle Aged. Neoplasm Invasiveness. Prognosis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581178.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CDX2 protein, human; 0 / GPI-Linked Proteins; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7; 0 / Membrane Glycoproteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / mesothelin
  •  go-up   go-down


78. Lázár G, Paszt A, Simonka Z, Rokszin R, Abrahám S: [Laparoscopic surgery in colorectal tumors]. Magy Onkol; 2010 Jun;54(2):117-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic surgery in colorectal tumors].
  • The minimally invasive technique, by means of the undoubted advantages of the method, has become fully accepted in the surgical treatments of the most benign and functional diseases.
  • Today it has been proven that the laparoscopic technique is safely usable also in the surgical treatment of colorectal tumors.
  • The authors, analyzing their own and the international experiences, present the laparoscopic surgical treatment of colorectal tumors.
  • Seventy-four patients were treated with laparoscopic-assisted colorectal intestinal resection in the Department of Surgery of the University of Szeged between January 1, 2005 and December 31, 2008.
  • The surgical indication was neoplastic colorectal lesion in 40 cases.
  • The histological processes of specimens justified tumor-free oral, aboral and circumferential resection in all cases.
  • Summarizing our own and international experiences it can be stated that the laparoscopic surgeries performed due to colorectal tumors are safe, and are also appropriate with respect to oncosurgery.
  • [MeSH-major] Colorectal Neoplasms / surgery. Digestive System Surgical Procedures / methods. Laparoscopy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colectomy / methods. Female. Humans. Hungary. Male. Middle Aged. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20576587.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


79. Huguet KL, Metzger PP, Menke DM: Colorectal lymphangioma. Am Surg; 2007 Apr;73(4):414-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal lymphangioma.
  • Lymphangiomas of the colon are historically rare benign tumors.
  • [MeSH-major] Cecal Neoplasms / diagnosis. Colonoscopy. Lymphangioma / diagnosis

  • Genetic Alliance. consumer health - Lymphangioma.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17439042.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Wang YC, Yu ZH, Liu C, Xu LZ, Yu W, Lu J, Zhu RM, Li GL, Xia XY, Wei XW, Ji HZ, Lu H, Gao Y, Gao WM, Chen LB: Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J Gastroenterol; 2008 May 21;14(19):3074-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients.
  • AIM: To evaluate the diagnostic role of serum RASSF1A promoter hypermethylation in gastric and colorectal adenocarcinoma.
  • METHODS: Methylation-specific polymerase chain reaction (MSPCR) was used to examine the promoter methylation status of the serum RASSF1A gene in 47 gastric adenocarcinoma patients, 45 colorectal adenocarcinoma patients, 60 patients with benign gastrointestinal disease (30 with benign gastric disease and 30 with benign colorectal disease), and 30 healthy donor controls.
  • A paired study of RASSF1A promoter methylation status in primary tumor, adjacent normal tissue, and postoperative serum were conducted in 25 gastric and colorectal adenocarcinoma patients who later were underwent surgical therapy.
  • RESULTS: The frequencies of detection of serum RASSF1A promoter hypermethylation in gastric (34.0%) and colorectal (28.9%) adenocarcinoma patients were significantly higher than those in patients with benign gastric (3.3%) or colorectal (6.7%) disease or in healthy donors (0%) (P < 0.01).
  • The methylation status of RASSF1A promoter in serum samples was consistent with that in paired primary tumors, and the MSPCR results for RASSF1A promoter methylation status in paired preoperative samples were consistent with those in postoperative serum samples.
  • The serum RASSF1A promoter hypermethylation did not correlate with patient sex, age, tumor differentiation grade, surgical therapy, or serum carcinoembryonic antigen level.
  • CONCLUSION: Aberrant CpG island methylation within the promoter region of RASSF1A is a promising biomarker for gastric and colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Colorectal Neoplasms / genetics. DNA Methylation. DNA, Neoplasm / blood. Promoter Regions, Genetic. Stomach Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2000 Dec;30(3):211-4 [11147802.001]
  • [Cites] Oncol Rep. 2007 Nov;18(5):1225-30 [17914577.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7034-8 [11585730.001]
  • [Cites] Mol Cell Biol. 2002 Jun;22(12):4309-18 [12024041.001]
  • [Cites] Oncogene. 2002 May 23;21(23):3792-5 [12032847.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1761-6 [12060614.001]
  • [Cites] Oncogene. 2002 Oct 17;21(47):7277-82 [12370819.001]
  • [Cites] Int J Cancer. 2002 Dec 20;102(6):623-8 [12448005.001]
  • [Cites] J Pathol. 2003 May;200(1):23-31 [12692837.001]
  • [Cites] Cancer Lett. 2003 Apr 25;193(2):207-16 [12706879.001]
  • [Cites] Cancer Lett. 2003 May 8;194(1):99-105 [12706863.001]
  • [Cites] Oncogene. 2003 Nov 6;22(50):8125-36 [14603253.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):96-100 [15185349.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4244-50 [15205337.001]
  • [Cites] Cancer Res. 1977 Mar;37(3):646-50 [837366.001]
  • [Cites] Oncology. 1989;46(5):318-22 [2779946.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5):556-60 [10528904.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3441-54 [15526363.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1219-25 [15709192.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1141-5 [15734995.001]
  • [Cites] Histol Histopathol. 2005 Apr;20(2):645-63 [15736067.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3682-90 [15867363.001]
  • [Cites] Biochemistry (Mosc). 2005 May;70(5):576-83 [15948711.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1293-6 [16001680.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5205-10 [16051962.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7653-9 [16140931.001]
  • [Cites] Oncogene. 2005 Nov 17;24(51):7630-4 [16007118.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):339-46 [16139926.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):315-9 [10888881.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):35669-72 [10998413.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):192-8 [16482617.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):4557-63 [16344548.001]
  • [Cites] Cell Oncol. 2006;28(5-6):247-57 [17167178.001]
  • [Cites] Lung Cancer. 2007 May;56(2):289-94 [17267069.001]
  • [Cites] BMC Cancer. 2007;7:120 [17608924.001]
  • [Cites] Int J Surg Pathol. 2007 Jul;15(3):242-51 [17652530.001]
  • [Cites] J Cell Sci. 2007 Sep 15;120(Pt 18):3163-72 [17878233.001]
  • [Cites] Mol Cell. 2007 Sep 21;27(6):962-75 [17889669.001]
  • [Cites] J Natl Cancer Inst. 2001 May 2;93(9):691-9 [11333291.001]
  • (PMID = 18494062.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2712178
  •  go-up   go-down


81. Czeczot H, Scibior-Bentkowska D, Skrzycki M, Majewska M, Podsiad M: [Lipid peroxidation level in gastrointestinal tract tumors]. Pol Merkur Lekarski; 2010 Nov;29(173):309-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lipid peroxidation level in gastrointestinal tract tumors].
  • Oxygen free radicals and their reactive derivatives participate in formation of chronic inflammation states, which facilitate development of gastrointestinal tract tumors.
  • The aim of the study was the determination of lipid peroxidation level in gastrointestinal tract tumors (stomach, liver, colon, and colorectal cancer to liver metastases).
  • MATERIAL AND METHODS: Materials for studies were obtained from 150 patients with gastrointestinal tract tumors: 10 with stomach cancer, 30 with malignant and benign liver cancers, 60 with primary colorectal cancer, and 50 with metachronous colorectal cancer liver metastases.
  • Tumor specimens, and normal adjacent tissues (6-7 cm from the edge of the tumor), which served as control tissue in studies, were collected from patients (with their consent) during surgery.
  • RESULTS: The study showed the highest concentration of TBARS in benign, and the lowest in malignant liver tumors.
  • Other types of gastrointestinal tumors studied, were characterized by similar levels of lipid peroxidation.
  • TBARS concentration in these tumors was approximately 2-fold higher than in malignant liver tumors and much lower than in benign tumors.
  • In all cancers of the digestive tract with the exception of malignant liver tumors increased level of TBARS was found, comparing with control tissue.
  • The level of lipid peroxidation in liver cirrhosis and malignant liver tumors was similar.
  • There were no significant differences in TBARS concentration in the tumors of particular sections of the intestine and normal colon.
  • The highest concentration of TBARS was found in G1 grade of colorectal cancer.
  • The highest level of lipid peroxidation, expressed as the concentration of TBARS was found in the I stage of colorectal cancer clinical advancement.
  • The changes of lipid peroxidation level--a marker of oxidative stress in gastrointestinal tumors appear to be closely associated with their development stages (liver cirrhosis/malignant liver cancer; colorectal cancer/colorectal cancer liver metastases) and are likely to create such conditions, in which cancerous cells may proliferate, undergo gradual dedifferentiation and malignancy, and generate metastases.
  • [MeSH-major] Gastrointestinal Neoplasms / metabolism. Lipid Peroxidation. Liver Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21268915.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


82. Holten-Andersen MN, Hansen U, Brünner N, Nielsen HJ, Illemann M, Nielsen BS: Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. Int J Cancer; 2005 Jan 10;113(2):198-206
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma.
  • We have previously demonstrated that TIMP-1 is elevated in blood from colorectal cancer patients and that high TIMP-1 levels predict poor prognosis.
  • To clarify the role of TIMP-1 in colorectal tumorigenesis, the expression pattern of TIMP-1 in benign and malignant colorectal tumors was studied.
  • In all of 24 cases of colorectal adenocarcinoma TIMP-1 mRNA was detected by in situ hybridization.
  • No TIMP-1 mRNA was seen in any of the cases in benign or malignant epithelial cells, in vascular cells or smooth muscle cells.
  • In conclusion, TIMP-1 expression is a rare event in benign human colon tissue but is highly expressed by myofibroblasts in association with invading colon cancer cells.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenoma / genetics. Adenoma / pathology. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Tissue Inhibitor of Metalloproteinase-1 / biosynthesis. Tissue Inhibitor of Metalloproteinase-1 / pharmacology
  • [MeSH-minor] Case-Control Studies. Cell Transformation, Neoplastic. Diagnosis, Differential. Fibroblasts / physiology. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Neoplasm Invasiveness. RNA, Messenger / analysis. RNA, Messenger / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15386409.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinase-1
  •  go-up   go-down


83. Nguyen KT, Gamblin TC, Geller DA: World review of laparoscopic liver resection-2,804 patients. Ann Surg; 2009 Nov;250(5):831-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUMMARY BACKGROUND DATA: Initially described for peripheral, benign tumors resected by nonanatomic wedge resections, minimally invasive liver resections are now being performed more frequently, even for larger, malignant tumors located in challenging locations.
  • Tumor type, operative characteristics, perioperative morbidity, and oncologic outcomes were tabulated.
  • Fifty percent were for malignant tumors, 45% were for benign lesions, 1.7% were for live donor hepatectomies, and the rest were indeterminate.
  • The 3-year overall and disease-free survival rates after laparoscopic liver resection for colorectal metastasis to the liver were 80% to 87% and 51%, respectively.
  • Oncologically, 3- and 5-year survival rates reported for hepatocellular carcinoma and colorectal cancer metastases are comparable to open hepatic resection, albeit in a selected group of patients.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg. 2015 Aug;262(2):e77-8 [24509191.001]
  • [CommentIn] Ann Surg. 2015 Aug;262(2):e78 [24670850.001]
  • (PMID = 19801936.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 114
  •  go-up   go-down


84. Qiu MZ, Yuan ZY, Luo HY, Ruan DY, Wang ZQ, Wang FH, Li YH, Xu RH: Impact of pretreatment hematologic profile on survival of colorectal cancer patients. Tumour Biol; 2010 Aug;31(4):255-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of pretreatment hematologic profile on survival of colorectal cancer patients.
  • Pretreatment hematologic abnormalities have been reported to have prognostic value in patients with solid tumors.
  • The aim of our study was to determine the prevalence of abnormalities in the hematologic profile in patients with colorectal cancer before treatment and to evaluate if such a profile could be used for prognostic evaluations.
  • We identified all patients in Cancer Center of Sun Yat-Sen University who were diagnosed as colorectal cancers between May 2005 and August 2009.
  • We identified 363 patients with colorectal cancer and 315 patients with benign diseases for the final analysis.
  • The percentages of leukocytosis, anemia, and thrombocytosis were significantly higher in colorectal cancer patients than in patients with benign diseases.
  • Univariate analysis showed that advanced tumor stages, leukocytosis, anemia, thrombocytosis, and low histological grade were all significantly associated with shorter survival.
  • The multivariate Cox analysis revealed that low histological grade, tumor stage, pretreatment anemia, and thrombocytosis remained independent prognostic variables for survival.
  • Anemia and thrombocytosis can be considered as useful prognostic markers in patients with colorectal cancer.
  • [MeSH-major] Anemia / diagnosis. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Leukocytosis / diagnosis. Thrombocytosis / diagnosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tex Med. 1990 Oct;86(10):80-3 [2247849.001]
  • [Cites] Clin Otolaryngol. 2008 Jun;33(3):245-51 [18559031.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2214-21 [11413508.001]
  • [Cites] Thromb Haemost. 2003 Jun;89(6):1098-106 [12783124.001]
  • [Cites] Eur Respir J. 1996 Sep;9(9):1826-30 [8880098.001]
  • [Cites] Thromb Haemost. 1998 May;79(5):916-8 [9609220.001]
  • [Cites] Ann Oncol. 2005 Jun;16(6):988-9 [15879160.001]
  • [Cites] Oncology. 2000 Feb;58(2):169-74 [10705245.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2399-405 [11745296.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1740-6 [15742330.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3 Suppl 7):2-6 [9671322.001]
  • [Cites] Urology. 2004 Mar;63(3):447-50 [15028435.001]
  • [Cites] Thromb Haemost. 1990 Dec 28;64(4):501-5 [1964750.001]
  • [Cites] Tumour Biol. 2000 Sep-Oct;21(5):309-14 [10940827.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):211-4 [14751160.001]
  • [Cites] J Am Coll Surg. 2004 May;198(5):737-41 [15110807.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):778-87 [12788185.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Dec;135(12):1783-90 [19551407.001]
  • [Cites] Clin Chim Acta. 2007 May 1;380(1-2):208-12 [17368603.001]
  • [Cites] JAMA. 1982 Feb 19;247(7):1004-6 [7035703.001]
  • [Cites] Ann Surg Oncol. 2002 Apr;9(3):287-91 [11923136.001]
  • [Cites] J Cell Mol Med. 2009 Mar;13(3):555-61 [18429933.001]
  • [Cites] J Clin Epidemiol. 1996 Dec;49(12):1373-9 [8970487.001]
  • [Cites] Oral Oncol. 2007 Mar;43(3):283-8 [16920387.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):335-42 [17504931.001]
  • [Cites] Hepatogastroenterology. 2004 May-Jun;51(57):847-53 [15143932.001]
  • [Cites] Nat Cell Biol. 2008 Mar;10 (3):295-305 [18297062.001]
  • (PMID = 20336401.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Skalicky T, Treska V, Liska V, Sutnar A, Molacek J, Mirka H, Ferda J, Ohlidalova K: The rare benign liver tumors. Bratisl Lek Listy; 2007;108(4-5):229-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The rare benign liver tumors.
  • As opposed to malignant secondary tumors, metastases of the colorectal carcinoma are benign tumors of the liver that are quite rare in the Czech Republic.
  • From the 55 patients operated on since 2000 at our department for benign liver tumors, the most frequent are haemangiomas, focal nodular hyperplasia (FNH) and hepatocelular adenoma.
  • Only 7.3% of them form a different histological type of a tumor than this most frequently occurring trio of tumors.
  • The authors describe three cases of rather rare liver tumors with benign behavior that have the potential of becoming malignant.
  • It concerns mucin producing biliary tumors, which correspond to the pancreatic intraductal papillary mucin tumor, hepatic cystadenoma with ovarian stroma and a liver hamartoma in an adult patient (Ref 13).
  • [MeSH-major] Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Cholangitis, Sclerosing / diagnosis. Cholangitis, Sclerosing / surgery. Cystadenoma / diagnosis. Cystadenoma / surgery. Female. Hemangioma, Cavernous / diagnosis. Hemangioma, Cavernous / surgery. Humans. Middle Aged. Pancreatic Ducts. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17694811.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  •  go-up   go-down


86. Kline RC, Bazzett-Matabele LB: Adnexal masses and malignancies of importance to the colorectal surgeon. Clin Colon Rectal Surg; 2010 Jun;23(2):63-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adnexal masses and malignancies of importance to the colorectal surgeon.
  • In this article, the authors review both benign and malignant ovarian masses, as the colorectal surgeon who encounters an adnexal mass at the time of surgery should be aware of the steps necessary for surgical staging and optimal tumor resection.Ovarian tumors-most of which are benign-are divided into three major categories, in order of frequency: epithelial, germ cell, and sex cord-stromal tumors.
  • Nonneoplastic conditions of the ovary that may present as adnexal masses include the following, according to World Health Organization (WHO) classification: pregnancy luteoma, hyperplasia of ovarian stroma, hyperthecosis, massive edema, solitary follicle cysts and corpus luteal cysts, multiple follicle cysts, and endometriosis.Epithelial ovarian tumors arise from the surface epithelium and can be benign or malignant.
  • Germ cell tumors are more likely to appear in females under 20 years, accounting for 70% of ovarian tumors in this age group.
  • Teratomas are the most common germ cell tumors.
  • Malignancies, in addition to malignant teratomas, include dysgerminomas, endodermal sinus tumors, and embryonal carcinomas.
  • The more common sex cord-stromal tumors include granulosa stromal cell tumors, Sertoli-Leydig cell tumors, and gynandroblastomas.Surgical staging and optimal tumor resection are also addressed, with a focus on epithelial malignancies, as they are the most relevant to colorectal surgeons.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):77-81 [11277654.001]
  • [Cites] JAMA. 1983 Dec 9;250(22):3072-6 [6358558.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jul;193(1):30-5 [16021055.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):185-91 [16216320.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):383-90 [17005244.001]
  • [Cites] Obstet Gynecol. 2009 Apr;113(4):775-82 [19305319.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(4):343-51 [2246093.001]
  • [Cites] Curr Top Pathol. 1989;78:85-109 [2651026.001]
  • [Cites] Environ Health Perspect. 1987 Aug;73:15-25 [3665859.001]
  • [Cites] Obstet Gynecol. 1983 Apr;61(4):413-20 [6828269.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):139-44 [2680797.001]
  • [Cites] Obstet Gynecol. 1989 Dec;74(6):921-6 [2685680.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):983-9 [3373267.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):34-7 [12079297.001]
  • (PMID = 21629623.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2967325
  • [Keywords] NOTNLM ; Adnexal masses / ovarian cancer / ovarian cysts
  •  go-up   go-down


87. Winter H, Lang RA, Spelsberg FW, Jauch KW, Hüttl TP: Laparoscopic colonoscopic rendezvous procedures for the treatment of polyps and early stage carcinomas of the colon. Int J Colorectal Dis; 2007 Nov;22(11):1377-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: Endoscopic treatment of large or colonoscopically inaccessible polyps or early stage tumors in the colon holds the risk of incomplete resection and colonic perforation.
  • A benign lesion was confirmed histologically in 31 patients.
  • In five cases, histopathologic diagnosis revealed a malignancy necessitating colonic surgery.
  • CONCLUSION: Rendezvous procedures offer a safe, minimal-invasive therapeutic approach allowing the resection of benign sessile or colonoscopically inaccessible localized polyps and of early stage colon cancer.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / therapy. Colonic Polyps / therapy. Colonoscopy / methods. Laparoscopy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Length of Stay. Male. Middle Aged. Neoplasm Staging. Postoperative Care. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):340-8 [12626909.001]
  • [Cites] Am Surg. 1988 Feb;54(2):61-3 [3341645.001]
  • [Cites] J Am Coll Surg. 1994 Nov;179(5):513-7 [7952451.001]
  • [Cites] Am J Surg. 1999 May;177(5):384-7 [10365875.001]
  • [Cites] Surg Endosc. 1997 Jun;11(6):643-4 [9171124.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1341-4 [9788858.001]
  • [Cites] Surg Technol Int. 2003;11:97-101 [12931289.001]
  • [Cites] Dis Colon Rectum. 1994 Aug;37(8):775-6 [7519975.001]
  • [Cites] Ann Intern Med. 1993 Oct 15;119(8):836-43 [8379605.001]
  • [Cites] Surg Laparosc Endosc. 1995 Apr;5(2):137-8 [7773461.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Dis Colon Rectum. 2001 Jan;44(1):112-8 [11805571.001]
  • [Cites] Surg Laparosc Endosc. 1994 Oct;4(5):382-3 [8000642.001]
  • [Cites] Dis Colon Rectum. 2001 May;44(5):746-8 [11357040.001]
  • [Cites] Arch Surg. 2005 Jul;140(7):692-7 [16027336.001]
  • [Cites] Mayo Clin Proc. 2000 Apr;75(4):344-8 [10761487.001]
  • [Cites] Surg Endosc. 1994 Nov;8(11):1352-3 [7831614.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1513-6 [14605571.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):505-8 [10215825.001]
  • [Cites] ANZ J Surg. 2003 Dec;73(12):988-95 [14632888.001]
  • (PMID = 17646999.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


88. Brozovich M, Read TE, Salgado J, Akbari RP, McCormick JT, Caushaj PF: Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution. Surg Endosc; 2008 Feb;22(2):506-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution.
  • PURPOSE: Endoscopically unresectable apparently benign colorectal polyps are considered by some surgeons as ideal for their early laparoscopic colectomy experience.
  • (1) a substantial fraction of patients undergoing laparoscopic colectomy for apparently benign colorectal neoplasia will have adenocarcinoma on final pathology; and (2) in our practice, we perform an adequate laparoscopic oncological resection for apparently benign polyps as evidenced by margin status and nodal retrieval.
  • METHODS: Data from a consecutive series of patients undergoing laparoscopic colectomy (on an intention-to-treat basis) for endoscopically unresectable neoplasms with benign preoperative histology were retrieved from a prospective database and supplemented by chart review.
  • The median nodal harvest was 12 and all resection margins were free of neoplasm.
  • Mean diameter of benign tumors was 3.2 cm (range 0.5-10.0cm) versus 3.9cm (range 1.5-7.5cm) for adenocarcinomas (p = 0.189, t - test).
  • CONCLUSION: A substantial fraction of endoscopically unresectable colorectal neoplasms with benign histology on initial biopsy will harbor invasive adenocarcinoma, some of advanced stage.
  • This finding supports the practice of performing oncological resection for all patients with endoscopically unresectable neoplasms of the colorectum.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Polyps / surgery. Colorectal Neoplasms / surgery. Laparoscopy
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Am J Surg. 1999 May;177(5):384-7 [10365875.001]
  • [Cites] Ann Surg. 1979 Dec;190(6):679-83 [518167.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1341-4 [9788858.001]
  • [Cites] AORN J. 1992 Dec;56(6):1068-73 [1463326.001]
  • [Cites] Dis Colon Rectum. 2006 Jun;49(6):879-82 [16598402.001]
  • [Cites] Surg Endosc. 2005 Sep;19(9):1252-5 [16132333.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):400-3 [17180271.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):505-8 [10215825.001]
  • (PMID = 17704872.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


89. Gollub MJ, Akhurst T, Markowitz AJ, Weiser MR, Guillem JG, Smith LM, Larson SM, Margulis AR: Combined CT colonography and 18F-FDG PET of colon polyps: potential technique for selective detection of cancer and precancerous lesions. AJR Am J Roentgenol; 2007 Jan;188(1):130-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUBJECTS AND METHODS: Eighteen patients with suspected colorectal polyps enrolled in this prospective study.
  • Sixteen benign polyps (10-25 mm) were not depicted on PET.
  • All nine cases of cancer (tumors measuring 11-60 mm) were detected with both PET and CTC.
  • The standard uptake value of malignant tumors ranged from 4 to 20 (mean, 9).
  • However, six benign flat polyps did not exhibit FDG avidity.
  • [MeSH-major] Colonic Polyps / diagnosis. Colonography, Computed Tomographic / methods. Fluorodeoxyglucose F18. Image Enhancement / methods. Positron-Emission Tomography / methods. Precancerous Conditions / diagnosis

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179355.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


90. Kostov D, Kobakov G, Dragnev N: [Operative-technical special features of the left lobectomy in colorectal cancer liver metastases]. Khirurgiia (Sofiia); 2006;(6):8-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Operative-technical special features of the left lobectomy in colorectal cancer liver metastases].
  • The indications of the liver resection are the primary and secondary malignant neoplasms of the liver, the benign liver tumors and some inflammatory diseases.
  • Approximately 10-30% of the patients with colorectal cancer liver metastases are suitable to a curative liver resection.
  • The aim of the study is to presenti of the operative-technical special features of the anatomical left lobectomy of patients with colorectal cancer liver metastases.
  • The indications of the operation of eight of them were solitary metastases, which had appeared after an operation on colorectal cancer and at one of them the resection was performed due to an angiosarcoma of the liver.
  • The liver resection highly improves the prognosis on the following conditions: a radical treatment of the primary tumor, an absence of local recurrence, an absence of an extrahepatic incidence of the primary tumor and a preservation of a sufficient capacity of the liver.
  • [MeSH-major] Adenocarcinoma / surgery. Colorectal Neoplasms / pathology. Hepatectomy / methods. Liver Neoplasms / surgery


91. Allgayer H: Pdcd4, a colon cancer prognostic that is regulated by a microRNA. Crit Rev Oncol Hematol; 2010 Mar;73(3):185-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The novel tumor suppressor Pdcd4 inhibits neoplastic transformation, tumor progression and translation.
  • Furthermore, we will review the first translational and clinical results concerning the prognostic value of Pdcd4, in particular our own data that show Pdcd4 to be a novel and independent prognostic factor in colorectal cancer, and a potential supportive diagnostic tool for discriminating normal colonic tissues from benign adenomas and colorectal carcinomas.
  • [MeSH-major] Apoptosis Regulatory Proteins / genetics. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / genetics. Gene Expression Regulation, Neoplastic. MicroRNAs / genetics. RNA-Binding Proteins / genetics
  • [MeSH-minor] Animals. Humans. Neoplasm Invasiveness / genetics. Neoplasm Metastasis / genetics. Prognosis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19836969.001).
  • [ISSN] 1879-0461
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / MicroRNAs; 0 / PDCD4 protein, human; 0 / RNA-Binding Proteins
  • [Number-of-references] 78
  •  go-up   go-down


92. Jeong WK, Park JW, Choi HS, Chang HJ, Jeong SY: Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center. Surg Endosc; 2009 Nov;23(11):2575-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center.
  • BACKGROUND: Transanal endoscopic microsurgery (TEM) is a minimally invasive alternative to transanal excision, enabling complete local excision of selected benign or malignant rectal tumors.
  • This study aimed to determine the surgical and oncologic results for rectal tumors excised by TEM.
  • METHODS: From November 2001 to October 2007, 45 patients underwent TEM for excision of adenoma (13 patients), carcinoid tumor (6 patients), and carcinoma (26 patients).
  • RESULTS: The median tumor distance from the anal verge was 7 cm (range, 3-15 cm), and the median tumor size was 17 mm (range, 2-60 mm).
  • No recurrence occurred for six patients with carcinoid tumors.
  • Histologic examination of the carcinomas showed pathologic tumor (pT) stage 0 (ypT0) in 2 patients, pT1 in 17 patients (including ypT1 in 1 patient), pT2 in 6 patients, and pT3 in 1 patient.
  • CONCLUSIONS: The TEM procedure is a safe and appropriate surgical treatment option for benign rectal tumors.
  • [MeSH-major] Anal Canal / surgery. Microsurgery / methods. Neoplasm Recurrence, Local / pathology. Proctoscopy / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / mortality. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Cancer Care Facilities. Carcinoid Tumor / mortality. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Korea. Male. Middle Aged. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Patient Selection. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Reoperation. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2001 Sep;234(3):352-8; discussion 358-9 [11524588.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):207-10 [8689164.001]
  • [Cites] Chirurg. 1984 Oct;55(10):677-80 [6510078.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1167-72 [15154642.001]
  • [Cites] Dis Colon Rectum. 1991 Oct;34(10):880-5 [1914721.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1003-8 [2754446.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] Surg Endosc. 2007 Jan;21(1):97-102 [17111281.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1283-7 [12739119.001]
  • [Cites] Am J Surg. 2007 Nov;194(5):694-8 [17936438.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):547-56 [16514476.001]
  • [Cites] Dis Colon Rectum. 2008 Jul;51(7):1026-30; discussion 1030-1 [18481147.001]
  • [Cites] Br J Surg. 2005 Dec;92(12):1546-52 [16252312.001]
  • [Cites] Dis Colon Rectum. 1996 Aug;39(8):886-92 [8756844.001]
  • [Cites] Am J Clin Oncol. 1994 Oct;17(5):411-6 [8092113.001]
  • [Cites] Colorectal Dis. 2004 Sep;6(5):350-5 [15335369.001]
  • [Cites] World J Surg. 1992 May-Jun;16(3):437-46 [1317077.001]
  • [Cites] Surg Endosc. 2002 Jun;16(6):989-95 [12163970.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1106-11 [14597451.001]
  • [Cites] Surg Endosc. 2007 Jun;21(6):970-4 [17285371.001]
  • [Cites] Br J Surg. 2007 May;94(5):627-33 [17335125.001]
  • [Cites] Dis Colon Rectum. 1996 Sep;39(9):969-76 [